CV Todd Eliot Golde, M.D., Ph.D. 2014
CURRICULUM VITAE
Todd Eliot Golde, M.D. Ph.D.
1220 SW 112th Street; Gainesville, FL 32607
email tgolde@ufl.edu or tegolde@gmail.com
SUMMARY
I am currently Director of the Center for Translational Research in Neurodegenerative Disease
(CTRND) at the University of Florida (UF), where I lead a high-impact program of scientific
discovery aimed at translating basic discoveries in neurodegenerative disease into diagnostics
and treatments for patients. In this capacity, as well as in my previous positions as Chair of the
Department of Neuroscience at Mayo Clinic Florida and member of the Mayo Foundation
Research Committee, I have gained substantial administrative and research strategic planning
experience in two very different organizations. At both Mayo and UF, I have promoted and
implemented a vision whereby wet-bench laboratories are closely tied to patient based
research activities, enabling ongoing interaction between clinical and basic investigators. The
success of the faculty in these groups during my tenure at both institutions has been
impressive, both in terms of scientific impact and per-investigator funding. With respect to my
own research program, I have made significant contributions to the Alzheimer’s disease (AD)
field, and my research activities remain robust and cutting-edge with a broadening focus that
extends to other neurodegenerative diseases, cancer, and even malaria. I also remain engaged
with biotechnology and large pharmaceuticals in order to advance academic-industry
partnerships. In addition to my research and intramural administrative activities, in recent
years I have been an active advocate for AD and neurodegenerative disease research at the
state, national and international levels.
PRESENT ACADEMIC RANK AND POSITION
2009-present: Professor of Neuroscience and Director, Center for Translational Research in
Neurodegenerative Disease University of Florida, College of Medicine Gainesville
Florida
Since joining UF in December 2009, I have recruited over muliple faculty to the center and built a
superb translational research program in Neurodegenerative diseases that currently has over
$4M/yr dollars in extramural support. The total staff of the CTRND is 60+ FTE and growing.
Since 2010 the Center faculty have authored or co-authored over 100 manuscripts primarily
relating to neurologic disorders. We are actively engaged in programmatic submissions of P50,
P30 and U01 grants. We have formed active partnerships relating to therapeutic discovery with
several academic institutions and are continually trying to foster strategic partnerships with
other academic institutions and the private sector.
PREVIOUS EMPLOYMENT WITH ACADEMIC RANK AND POSITION
2
CV Todd Eliot Golde, M.D., Ph.D. 2014
2003-2009: Chair of Department of Neuroscience, Mayo Clinic College of Medicine, Mayo Clinic
Florida
During my tenure as chair, the Department of Neuroscience made many groundbreaking
discoveries in the neurodegenerative field. Our group was incredibly productive with hundreds
of publications. Objectively, many of these were of very high impact. On a yearly basis a
publication or publications from the Departmental faculty were often among the 10 most highly
cited primary research papers in the Alzheimer’s and Parkinson’s field, and each year we had
many publications among the 100 most cited in the field. Our extramural grant portfolio
exceeded $10M/yr from 2005-2009 with a census of 11-14 PIs. The Department also had an
excellent record for developing junior faculty. Many of these individuals, such as Drs.
Rademakers, Petrucelli, Eckman, Ertekin-Taner, are considered some of the rising (or perhaps
risen) stars in their areas of investigation.
2005-2009: Professor of Neuroscience and Consultant, Mayo Clinic College of Medicine, Mayo
Clinic Florida
2001-2005: Associate Professor of Neuroscience, Mayo Clinic College of Medicine, Mayo Clinic
Florida
1997-2001: Assistant Professor of Pharmacology, Mayo Clinic College of Medicine, Mayo Clinic
Florida
1996-1997: Assistant Professor of Pathology and Laboratory Medicine, University of
Pennsylvania School of Medicine
RESIDENCY AND POSTDOCTORAL TRAINING
1995-1996: Chief Resident Clinical Pathology and Laboratory Medicine, University of
Pennsylvania School of Medicine, Hospital of the University of Pennsylvania
1994-1996: Resident Clinical Pathology and Laboratory Medicine, University of Pennsylvania
School of Medicine, Hospital of the University of Pennsylvania
1991-1992: Postdoctoral Fellow, Neuroscience Training Grant, Case Western Reserve University
“Analysis of wild-type and mutant β amyloid protein precursor”. Mentor: Steven G.
Younkin MD PhD.
1990-1991: Research Associate, Institute of Pathology Case Western Reserve University
“Analysis of the β amyloid protein precursor”. Mentor: Steven G. Younkin MD PhD.
EDUCATIONAL BACKGROUND
1985-1994:
Case Western Reserve University, NIH funded Medical Scientist Training Program
(MSTP) MD PhD.
MD D awarded 1994
PhD in Pathology awarded 1991
1981-1985:
Amherst College, Biology and Immunology, B.A (Magna Cum Laude).
3
CV Todd Eliot Golde, M.D., Ph.D. 2014
MEDICAL LICENSURE
Passed Step 1, Step 2, and Step 3 USMLE.
Eligible for Clinical Pathology Board as of June 1996
HONORS AND AWARDS
2014: 2014 College of Medicine Basic Science Research Award, University of Florida
2013:
2012:
Member, NIH Alzheimer's Disease Technical Team Target Validation Consortium
Member, National Alzheimer’s Association Medical and Scientific Advisory
Committee
2012:
Member, State of Florida AD Purple Ribbon Task Force (Speaker of the House of
Representative’s Appointment)
2010:
Stephen DeArmond Lecturer, American Association of Neuropathology
2010:
Member, State of Florida Alzheimer’s Advisory Board (Governor’s Appointment)
2010:
MetLife Award for Medical Research, MetLife Foundation
2010:
Thome Award in Alzheimer's Disease Drug Discovery Research, Edward N. and Della
L. Thome Memorial Foundation
2010:
Ellison Medical Foundation Senior Scholar Award
2008:
Health Care Hero in Research Jacksonville Business Journal
2007:
Coins for Alzheimer’s Research Trust (CART) Award, American Federation for Aging
Research (AFAR)
2006:
Speaker, Commemoration of 100 Years of Alzheimer’s Research, Tubbingen,
Germany
2005:
Zenith Award, Alzheimer’s Association
2001:
Outstanding Contributor, Alzheimer’s Research Forum
1998:
Ellison Medical Foundation New Investigator Scholar
1997:
Paul Beeson Physician Faculty Scholar (American Federation for Aging Research
AFAR/The Hartford Foundation)
1993:
Experimental Pathologist-in-Training Award. American Society for Investigative
Pathology. Awarded to a junior pathologist, below the faculty level, in recognition of
their research work.
1985:
BA. Magna Cum Laude. Amherst College, Department of Biology.
1984-85: The Oscar E. Schotte Award. Amherst College, warded to a senior student for the
outstanding Honor's thesis in the Department of Biology.
MEMBERSHIP AND ACTIVITIES IN THE PROFESSION
Professional Societies and Organizations
2012:
2011:
Alzheimer’s Association Medical and Scientific Advisory Board Member
Alzheimer’s Association International Conference Planning Committee
4
CV Todd Eliot Golde, M.D., Ph.D. 2014
2010-current:
1996-2000:
1987-current:
Alzheimer’s Association International Society to Advance Alzheimer
Research and Treatment (ISTAART)
Member, Association for Molecular Pathology
Member, Society for Neuroscience
Review Boards, Foundations
2015-Current Bright Focus Foundation
2014-current: W Garfield Weston Foundation
2014-current: Alzheimer’s Drug Discovery Foundation
2012- current: Alzheimer’s Association, MSAC final ranking of grants for multiple programs and
provides input on funding initiatives.
2001-2011: Alzheimer’s Association Grants Programs
2000-current: American Federation for Aging Research
2007-current: American Health Assistance Foundation
2010:
French ANR
2010:
Welcome Trust (2010)
2001-current: Canadian Alzheimer’s Association (ad hoc, intermittent)
National Institute of Health (CSR) Review Panels
1998-99:
2001-2002:
2002:
2004-2007:
2009:
2007, 2009:
2009:
2012:
MDCN-2, ad hoc
MSD-B, ad hoc
M. J. Fox R21 SEP, MDCN-3 ad hoc
CDIN, member
CMND, ad hoc
ZRG1 BDCN SEP Chair
ZAG1 SEP RC2 grants Chair
ZNS1 SRB G (58) Chair
Scientific Advisory Boards
2013-current: Foundation for the National Institutes of Health (FNIH) Accelerating Medicines
Partnership (AMP)
2012-2013: Purple Ribbon Task Force for Alzheimer’s Disease, Florida Speaker of the House
of Representatives Appointment
2012-current: Medical and Scientific Advisory Council for the National Alzheimer’s Association
2011-current: NIAGADS NIA Genetics of Alzheimer’s Disease Data Storage Site Advisory
Committee
2010-current: Department of Elder Affairs, Alzheimer’s Disease Advisory Committee (ADI),
Governors Appointment.
2006-current: American Health Assistance Foundation Alzheimer’s Advisory Board (renamed
BrightFocus Foundation 2013)
5
CV Todd Eliot Golde, M.D., Ph.D. 2014
2003-current: American Federation for Aging Research’s (AFAR) National Scientific Advisory
Council (NSAC).
Other Activities, Organizer/Participant/Reviewer
2015:
08/10/11
04/06/11
2008-2010
2010
2010
2008
06/06/07
2006-2009
2007-2009
Co-Organizer of the EMBO conference for Neurodegeneration in 2015
Participant, The Biology of Aging Colloquium by The Ellison Medical Foundation.
Woods Hole, MA.
Participant, 2011 Philip Hauge Abelson Advancing Science Symposium on
“Breaching Barriers in Alzheimer’s Disease.” Washington, DC.
Coordinated a review series for Molecular Neurodegeneration on “What kills
Neurons in Neurodegenerative Disease
Extramural Advisory Board Member Review Panel for the Institute for
Neurodegenerative Diseases UCSF (Dr. Stanley Prusiner)
Extramural Advisory Board Member Review Panel University of Leuven
Department of Molecular and Developmental Genetics
Developed the Discovery Tract Program BioFlorida 2008, Amelia Island Florida
Chair Biomarkers Preconference. Alzheimer’s Prevention Conference,
Washington, DC.
Development of Research Collaboration between Mayo and FSU
Sponsored Research Program between Mayo and Lundbeck Inc.
Editorial Boards
2012-current:
2009-current:
2006-current:
2000-2010:
2007-current:
Associate Editor – Journal of Neuroscience
Co-Editor in Chief - Alzheimer’s Research and Therapy
Associate Editor - Molecular Neurodegeneration
Section Editor - Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease
Consulting Editor Journal of Clinical Investigation
Journal Review Activities
Acta Neuropathology
American Journal of Pathology
Annals of Neurology
Brain
Biochemistry
Biochimica et Biophysica Acta – BBA
Cell
Experimental Cell Research
EMBO
EMBO Molecular Medicine
Experimental Neurology
6
CV Todd Eliot Golde, M.D., Ph.D. 2014
Journal of Alzheimer’s Disease
Journal of Biological Chemistry
Journal of Cell Science
Journal of Clinical Investigation
Journal of the Federation of American Societies for Experimental Biology - FASEB
Journal of Neurochemistry
Journal of Neuroscience
Molecular Medicine
Molecular Neurodegeneration
Mount Sinai Journal of Medicine
Nature
Nature Genetics
Nature Medicine
Nature Biotechnology
Nature Neuroscience
Nature Communications
Neurobiology of Aging
Neurobiology of Disease
Neuron
Neurology
PNAS
PLOS One
Science
Science Translational Medicine
Trends in Pharmacological Science
UNIVERSITY GOVERNANCE AND SERVICE
Institutional
2014-current:
2014-current:
2014-current:
2014-current:
2014-current:
Chair, Search Committee, College of Medicine, Anesthesiology, UF
Member, Space Strategic Planning, College of Medicine, UF
Member, Space Strategic Planning Work Group for HSC, UF
Public Private Partnershp Strategic Planning Work Group for HSC, UF
Member, Subcommittee for Accreditation, LCME Facilities, College of Medicine,
UF.
2010-current: Member, UF McKnight Brain Institute Executive Committee that provides
oversight and strategic planning for Neuromedicine activities at the University of
Florida.
2010-current: Member, Lake Nona Leadership Council for the University Of Florida College Of
Pharmacy’s Center for Pharmacometrics and Systems Pharmacology in Lake
Nona Florida
2009-current: Member, UF College of Medicine Research Leadership Committee
7
CV Todd Eliot Golde, M.D., Ph.D. 2014
2009-current: UF, Chair, CTRND Advisory Committee
2006-2009: Mayo Clinic SAG Discovery Translation Fund Review
2006-2009: Member, Mayo Foundation Research Committee. The Committee was
responsible for oversight of research and research strategic planning across the
Mayo foundation (Rochester, Florida, Arizona)
2004-2009: Member, Mayo Clinic College of Medicine Communications Committee
2001- 2009: Member, Mayo Clinic Florida Research Committee
1999-2003: Member, Mayo Graduate School Education Committee
Departmental
2003-2009
2002-2009
2001-2009
1999-2003
Chair, Mayo Clinic Neuroscience Department Faculty Committee
Member, Mayo Clinic Florida Neuroscience Department Strategic Planning
Committee
Member, Mayo Clinic Florida Neuroscience Department Executive Committee
Graduate Education Coordinator, Mayo Clinic Florida
PHARMACEUTICAL CONSULTING
2012:
2011:
2010:
2009:
2009:
2008-2009:
2008:
2005:
2004:
2003, 2005:
1999-2005:
Roche/Genentech AD Immunotherapy advisory panel
Novartis NEP inhibitor Program
JANNSEN AD Advisory Board
Wyeth/Elan Bapineuzimab Advisory Panel
Sonexa Inc
Elan SAB Alzheimer’s disease
Lundbeck Immunotherapy Program
Satoris Inc
Novartis CNS Neurodegeneration Program
Bristol Myers Squibb Neurodegeneration program
Pfizer Inc gamma-secretase program
PATENTS
Issued
2003 “BRI Constructs and Methods of Using” US2003221204, WO03002754, AU2002315494,
WO03002754. : T. Golde, E. McGowan, and P. Das.
2001 “Method of reducing Abeta42 and treating diseases” and “Aß42 lowering agents”
US2006004086, AU2005201819, WO0178721. Inventors: E. Koo, D. Galsko, S. Weggen,
and T. Golde.
Pending
8
CV Todd Eliot Golde, M.D., Ph.D. 2014
2013 COMPOUNDS FOR TREATING NEURODEGENERTIVE PROTEINOPTHIES. Inventors: T.
Golde, P. Chakrabarty, Y. Levites.
2010 US2011262387 METHODS AND MATERIALS FOR REDUCING OR SUPPRESSING AMYLOID
DEPOSITION Inventors: T. Golde, P. Chakrabarty, P. Das
2008 US2011021471 (A1) REDUCING ABETA42 LEVELS AND ABETA AGGREGATION. Inventors
Todd E Golde, Abdul Fauq, Thomas B Ladd and Thomas L Kukar and Craig Zwizinski
2007 WO2009009396 BRI POLYPEPTIDES AND REDUCING AB AGGREGATION. Inventors T. E.
Golde, J. Kim, Y. Levites, K Jansen, V. Miller, and S. Younkin.
2006 US2011206670 Methods and Materials related to Anti-Amyloid Antibodies. Inventors T.
E. Golde, Y. Levites, K. Jansen-West, and P. Das. Describes a novel therapeutic approach
for AD.
2006 WO2008045962 Methods and Materials related to Anti Aß. Inventors T.E. Golde, P. Das,
K. Jansen West, and Y. Levites.
2005 WO2007047436 Methods and Materials for producing a generic anti-amyloid immune
response in mammals. Inventors T.E. Golde. and P. Das.
CONTRIBUTION TO DISCIPLINE/RESEARCH NARRATIVE
I believe I have made significant contributions to the Alzheimer’s disease (AD) field. As a MD
PhD student and postdoc with Dr. Steven Younkin, I played a pivotal role in studies showing
that the amyloid  protein (A) was a normal metabolite and that mutations that cause AD
alter A production in a manner that promote A aggregation. These studies provided pivotal
support for the A aggregate (amyloid) hypothesis of AD and enabled drug discovery programs
aimed at altering A accumulation.
As an independent investigator, my initial research focus centered on understanding how
different species of A peptides were produced. At that time, the enzymes that generated A
from its precursor, APP, were not identified. Especially enigmatic was the intramembrane
cleavage of APP, referred to as -secretase, which produces Aß peptides with different carboxyl
termini. As AD causing mutations shift -secretase cleavage to favor production of the more
amyloidogenic A42, a detailed understanding of the -secretase cleavage was important. We
established that certain small molecule -secretase inhibitors preferentially inhibited A40
production indicating that -secretase had multiple proteolytic activities and provided the
impetus to screen for small molecules that preferentially inhibited A42.
In subsequent studies conducted in collaboration with Dr. Edward Koo’s laboratory (UCSD), we
demonstrated that select non-steroidal anti-inflammatory agents (NSAIDs) could modulate
A42 production and that this effect was attributable to direct alteration of -secretase activity.
These data were significant as epidemiologic studies showed an association between NSAIDs
use and reduced risk for development of AD. We reasoned that the A42 lowering action of
certain NSAIDs could account for this association. Subsequently we identified compounds that
lowered A42 but lacked cyclooxygenase activity. Our evidence provided the rationale for
9
CV Todd Eliot Golde, M.D., Ph.D. 2014
Myriad Genetics and now many other pharmaceutical companies to develop and test what we
now refer to as -secretase modulators as potential therapeutics for AD.
We have also identified compounds that increased A42; thus, mimicking the effect of AD
causing mutations and raising the possibility that small molecules could modulate -secretase
cleavage in a way that might increase one’s risk for AD. Finally, we demonstrated that the
target of NSAID like -secretase modulators was not the enzyme but the substrate. These later
studies not only have implications for AD therapeutics but also more generally broaden the
notion of what is “druggable.” Most recently we have identified a cholesterol metabolite as a
putative endogenous -secretase modulator.
In addition to studies on -secretase and -secretase modulators, another focus of my
laboratory has been to try to understand how anti-A immunotherapy works. These studies
have led to a number of publications that demonstrate many of the assumptions about how
this form of AD therapy works are not likely to be correct. Based on these data, we are
currently developing anti-amyloid based antibodies and amyloid based vaccines.
Another aspect my work that extends prior studies on A production and modulators of A
production involved the development of novel models of AD. A number of groups had
previously attempted to develop methods to express individual A peptides, with little success.
We developed a novel fusion protein strategy that enabled the production of individual A
peptides that were efficiently secreted. In collaboration with Dr. Eileen McGowan, we
developed transgenic mice that produce high levels of either A40 or A42. We have used
these mice to establish that A42 is essential for A accumulation in the brain and to show
that A40 actually inhibits A deposition. These studies further establish the rationale for
selective targeting of A42 and reveal an unexpected protective role for A40.
A parallel area of interest has been the therapeutic utility of targeting intramembrane cleaving
protease in a variety of indications. In 2002, in collaboration with Dr. Chris Ponting, we
identified a family of intramembrane protease that was related to -secretase. In work
conducted in collaboration with Drs. Osborne (UMASS), Miele (Loyola/U. Miss), and Greenbaum
(U Penn), we are evaluating targeting these proteases in cancer, immunologic disease, and
malaria. We have recently published proof of concept studies that malarial signal peptidase is a
superb anti-malarial drug target.
Most recently, my research has expanded into the area of innate immunity’s role in
neurodegenerative disease. Recent work from my lab has challenged a long-standing
hypothesis that inflammatory processes in AD accelerate Aβ deposition. Recently published
studies also reveal a potential novel role of interferon- in nigrostriatal degeneration. We have
now expanded these studies to broadly explore immune modulators as mediators of
neurodegenerative pathways. Notably, these studies have utilized a novel method for gene
delivery to the brain that results in widespread transduction, and we are currently evaluating
how we may harness innate immunity for therapeutic benefit in AD, PD, and ALS.
10
CV Todd Eliot Golde, M.D., Ph.D. 2014
PUBLICATIONS in reverse chronologic order.
Current h index (ISI) = 62, > 15,000 cites
200+ peer reviewed manuscripts
1.
Jung JI, Price AR, Ladd TB, Ran Y, Park HJ, Ceballos-Diaz C, Smithson L, Hochhaus G, Tang
Y, Akula R, Ba S, Koo EH, Shapiro G, Felsenstein KM, Golde TE. Cholestenoic acid, an
endogenous cholesterol metabolite, is a potent gamma-secretase modulator. Molecular
Neurodegeneration. in press.
2.
Yun J, Espinoza I, Pannuti A, Romero D, Martinez L, Caskey M, Stanculescu A, Bocchetta
M, Rizzo P, Band V, Band H, Kim HM, Park SK, Kang KW, Avantaggiati ML, Gomez CR,
Golde T, Osborne B, Miele L. p53 Modulates Notch Signaling in MCF-7 Breast Cancer
Cells by Associating with the Notch Transcriptional Complex via MAML1. Journal of
cellular physiology. 2015.
3.
Ran Y, Ladd GZ, Ceballos-Diaz C, Jung JI, Greenbaum D, Felsenstein KM, Golde TE.
Differential Inhibition of Signal Peptide Peptidase Family Members by Established
gamma-Secretase Inhibitors. PloS one. 2015;10(6):e0128619. PMCID: 4457840.
4.
4. Park HJ, Ran Y, Jung JI, Holmes O, Price AR, Smithson L, Ceballos-Diaz C, Han C, Wolfe
MS, Daaka Y, Ryabinin AE, Kim SH, Hauger RL, Golde TE, Felsenstein KM. The stress
response neuropeptide CRF increases amyloid-beta production by regulating gammasecretase activity. The EMBO journal. 2015;34(12):1674-86.
5.
Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, DiNunno N, Rosario
AM, Cruz PE, Verbeeck C, Sacino A, Nix S, Janus C, Price ND, Das P, Golde TE. IL-10 Alters
Immunoproteostasis in APP Mice, Increasing Plaque Burden and Worsening Cognitive
Behavior. Neuron. 2015 Feb 4;85(3):519-33.
6.
Ofori E, Pasternak O, Planetta PJ, Burciu R, Snyder A, Febo M, Golde TE, Okun MS,
Vaillancourt DE. Increased free water in the substantia nigra of Parkinson's disease: a
single-site and multi-site study. Neurobiol Aging. 2015 Feb;36(2):1097-104.
7.
Levites Y, O'Nuallain B, Puligedda RD, Ondrejcak T, Adekar SP, Chen C, Cruz PE, Rosario
AM, Macy S, Mably AJ, Walsh DM, Vidal R, Solomon A, Brown D, Rowan MJ, Golde TE,
Dessain SK. A human monoclonal IgG that binds abeta assemblies and diverse amyloids
exhibits anti-amyloid activities in vitro and in vivo. The Journal of neuroscience : the
official journal of the Society for Neuroscience. 2015;35(16):6265-76. PMCID: 4405548.
8.
Chakrabarty P, Hudson Iii VJ, Sacino AN, Brooks MM, D'Alton S, Lewis J, Golde TE,
Giasson BI. Inefficient induction and spread of seeded tau pathology in P301L mouse
model of tauopathy suggests inherent physiological barriers to transmission. Acta
neuropathologica. 2015.
9.
Jung JI, Premraj S, Cruz PE, Ladd TB, Kwak Y, Koo EH, Felsenstein KM, Golde TE, Ran Y.
11
CV Todd Eliot Golde, M.D., Ph.D. 2014
Independent relationship between amyloid precursor protein (APP) dimerization and γsecretase processivity. PLoS One. 2014 Oct 28;9(10):e111553.
10.
Ayers JI, Fromholt S, Sinyavskaya O, Siemienski Z, Rosario AM, Li A, Crosby KW, Cruz PE,
DiNunno NM, Janus C, Ceballos-Diaz C, Borchelt DR, Golde TE, Chakrabarty P, Levites Y.
Widespread and Efficient Transduction of Spinal Cord and Brain Following Neonatal AAV
Injection and Potential Disease Modifying Effect in ALS Mice. Mol Ther. 2015
Jan;23(1):53-62.
11.
Kim JY, Grunke SD, Levites Y, Golde TE, Jankowsky JL. Intracerebroventricular viral
injection of the neonatal mouse brain for persistent and widespread neuronal
transduction. J Vis Exp. 2014 Sep 15;(91):51863.
12.
Sacino AN, Brooks M, McKinney AB, Thomas MA, Shaw G, Golde TE, Giasson BI. Brain
injection of α-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury
marker. J Neurosci 2014 Sep 10;34(37):12368-78.
13.
Sacino AN, Brooks M, Thomas MA, McKinney AB, Lee S, Regenhardt RW, McGarvey NH,
Ayers JI, Notterpek L, Borchelt DR, Golde TE, Giasson BI. Intramuscular injection of αsynuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in
transgenic mice. Proc Natl Acad Sci U S A 2014 Jul 22;111(29):10732-7.
14.
Rutherford NJ, Moore BD, Golde TE, Giasson BI. Divergent effects of the H50Q and G51D
SNCA mutations on the aggregation of α-synuclein. J Neurochem 2014 Dec;131(6):85967.
15.
Shin HM, Tilahun ME, Cho OH, Chandiran K, Kuksin CA, Keerthivasan S, Fauq AH, Golde
TE, Miele L, Thome M, Osborne BA, Minter LM. NOTCH1 Can Initiate NF-κB Activation
via Cytosolic Interactions with Components of the T Cell Signalosome. Front Immunol.
2014 May 26;5:249.
16.
March A, Borchelt D, Golde T, Janus C. Differences in memory development among
C57BL/6NCrl, 129S2/SvPasCrl, and FVB/NCrl mice after delay and trace fear
conditioning. Comp Med 2014 Feb;64(1):4-12.
17.
Sacino AN, Brooks M, Thomas MA, McKinney AB, McGarvey NH, Rutherford NJ,
Ceballos-Diaz C, Robertson J, Golde TE, Giasson BI. Amyloidogenic α-synuclein seeds do
not invariably induce rapid, widespread pathology in mice. Acta Neuropathol. 2014 May;
1275(5):645-65.
18.
Born HA, Kim JY, Savjani RR, Das P, Dabaghian YA, Guo Q, Yoo JW, Schuler DR, Cirrito JR,
Zheng H, Golde TE, Noebels JL, Jankowsky JL. Genetic suppression of transgenic APP
rescues Hypersynchronous network activity in a mouse model of Alzeimer's disease. J
Neuroscience 2014 Mar 12;34(11):3826-40.
19.
Jung JI, Ran Y, Cruz PE, Rosario AM, Ladd TB, Kukar TL, Koo EH, Felsenstein KM, Golde
12
CV Todd Eliot Golde, M.D., Ph.D. 2014
TE. Complex relationships between substrate sequence and sensitivity to alterations in
γ-secretase processivity induced by γ-secretase modulators. Biochemistry 2014 Apr
1;53(12):1947-57.
20.
Dongre A, Surampudi L, Lawlor RG, Fauq AH, Miele L, Golde TE, Minter LM, Osborne BA.
Non-Canonical Notch Signaling Drives Activation and Differentiation of Peripheral
CD4(+) T Cells. Front Immunol 2014 Feb12;5:54.
21.
Ran Y, Cruz PE, Ladd TB, Fauq AH, Jung JI, Matthews J, Felsenstein KM, Golde TE.
gamma-Secretase Processing and Effects of gamma-Secretase Inhibitors and Modulators
on Long Abeta Peptides in Cells. The Journal of biological chemistry 2014;289:327687.3916530.
22.
Janus C, Golde T. The effect of brief neonatal cryoanesthesia on physical development
and adult cognitive function in mice. Behavioural brain research 2014;259:25360.3883048.
23.
Golde TE. Open questions for Alzheimer's disease immunotherapy. Alzheimer's research
& therapy 2014;6:3.
24.
Sacino AN, Thomas MA, Ceballos-Diaz C, Cruz PE, Rosario AM, Lewis J, Giasson BI, Golde
TE. Conformational templating of alpha-synuclein aggregates in neuronal-glial cultures.
Molecular neurodegeneration 2013;8:17.3671973.
25.
Sacino AN, Brooks M, McGarvey NH, McKinney AB, Thomas MA, Levites Y, Ran Y, Golde
TE, Giasson BI. Induction of CNS alpha-synuclein pathology by fibrillar and nonamyloidogenic recombinant alpha-synuclein. Acta neuropathologica communications
2013;1:38.3893388.
26.
Rutherford NJ, Lewis J, Clippinger AK, Thomas MA, Adamson J, Cruz PE, Cannon A, Xu G,
Golde TE, Shaw G, Borchelt DR, Giasson BI. Unbiased screen reveals ubiquilin-1 and -2
highly associated with huntingtin inclusions. Brain research 2013;1524:62-73.3914001.
27.
Roderick JE, Gonzalez-Perez G, Kuksin CA, Dongre A, Roberts ER, Srinivasan J,
Andrzejewski C, Jr., Fauq AH, Golde TE, Miele L, Minter LM. Therapeutic targeting of
NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic
anemia. The Journal of experimental medicine 2013;210:1311-29.3698520.
28.
Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE, Felsenstein KM.
Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse
deficits in AD mouse models". Science 2013;340:924-d.
29.
Melnikova T, Fromholt S, Kim H, Lee D, Xu G, Price A, Moore BD, Golde TE, Felsenstein
KM, Savonenko A, Borchelt DR. Reversible pathologic and cognitive phenotypes in an
inducible model of Alzheimer-amyloidosis. The Journal of neuroscience : the official
journal of the Society for Neuroscience 2013;33:3765-79.3711622.
13
CV Todd Eliot Golde, M.D., Ph.D. 2014
30.
Kim JY, Ash RT, Ceballos-Diaz C, Levites Y, Golde TE, Smirnakis SM, Jankowsky JL. Viral
transduction of the neonatal brain delivers controllable genetic mosaicism for visualising
and manipulating neuronal circuits in vivo. The European journal of neuroscience
2013;37:1203-20.3628093.
31.
Kim J, Chakrabarty P, Hanna A, March A, Dickson DW, Borchelt DR, Golde T, Janus C.
Normal cognition in transgenic BRI2-Abeta mice. Molecular neurodegeneration
2013;8:15.3658944.
32.
Jung JI, Ladd TB, Kukar T, Price AR, Moore BD, Koo EH, Golde TE, Felsenstein KM.
Steroids as gamma-secretase modulators. FASEB journal : official publication of the
Federation of American Societies for Experimental Biology 2013;27:3775-85.3752532.
33.
Golde TE, Streit WJ, Chakrabarty P. Alzheimer's disease risk alleles in TREM2 illuminate
innate immunity in Alzheimer's disease. Alzheimer's research & therapy
2013;5:24.3706774.
34.
Golde TE, Lewis J, McFarland NR. Anti-tau antibodies: hitting the target. Neuron
2013;80:254-6.
35.
Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L. gamma-Secretase inhibitors and
modulators. Biochimica et biophysica acta 2013;1828:2898-907.3857966.
36.
Golde TE, Borchelt DR, Giasson BI, Lewis J. Thinking laterally about neurodegenerative
proteinopathies. The Journal of clinical investigation 2013;123:1847-55.3635732.
37.
Golde T, Schuldt C, Schnauss J, Strehle D, Glaser M, Kas J. Fluorescent beads disintegrate
actin networks. Physical review E, Statistical, nonlinear, and soft matter physics
2013;88:044601.
38.
Galasko D, Golde TE, Scheltens P. Progress in Alzheimer's disease research circa 2013: Is
the glass half empty or half full? Alzheimer's research & therapy 2013;5:26.3706787.
39.
Galasko D, Golde TE. Biomarkers for Alzheimer's disease in plasma, serum and blood conceptual and practical problems. Alzheimer's research & therapy 2013;5:10.3706797.
40.
Clippinger AK, D'Alton S, Lin WL, Gendron TF, Howard J, Borchelt DR, Cannon A,
Carlomagno Y, Chakrabarty P, Cook C, Golde TE, Levites Y, Ranum L, Schultheis PJ, Xu G,
Petrucelli L, Sahara N, Dickson DW, Giasson B, Lewis J. Robust cytoplasmic accumulation
of phosphorylated TDP-43 in transgenic models of tauopathy. Acta neuropathologica
2013;126:39-50.3690181.
41.
Chu J, Li JG, Ceballos-Diaz C, Golde T, Pratico D. The influence of 5-lipoxygenase on
Alzheimer's disease-related tau pathology: in vivo and in vitro evidence. Biological
psychiatry 2013;74:321-8.3726558.
42.
Chakrabarty P, Rosario A, Cruz P, Siemienski Z, Ceballos-Diaz C, Crosby K, Jansen K,
14
CV Todd Eliot Golde, M.D., Ph.D. 2014
Borchelt DR, Kim JY, Jankowsky JL, Golde TE, Levites Y. Capsid serotype and timing of
injection determines AAV transduction in the neonatal mice brain. PloS one
2013;8:e67680.3692458.
43.
Blair LJ, Nordhues BA, Hill SE, Scaglione KM, O'Leary JC, 3rd, Fontaine SN, Breydo L,
Zhang B, Li P, Wang L, Cotman C, Paulson HL, Muschol M, Uversky VN, Klengel T, Binder
EB, Kayed R, Golde TE, Berchtold N, Dickey CA. Accelerated neurodegeneration through
chaperone-mediated oligomerization of tau. The Journal of clinical investigation
2013;123:4158-69.3784538.
44.
Verbeeck C, Deng Q, Dejesus-Hernandez M, Taylor G, Ceballos-Diaz C, Kocerha J, Golde
T, Das P, Rademakers R, Dickson DW, Kukar T. Expression of Fused in sarcoma mutations
in mice recapitulates the neuropathology of FUS proteinopathies and provides insight
into disease pathogenesis. Molecular neurodegeneration 2012;7:53.3519790.
45.
Tebbenkamp AT, Crosby KW, Siemienski ZB, Brown HH, Golde TE, Borchelt DR. Analysis
of proteolytic processes and enzymatic activities in the generation of huntingtin nterminal fragments in an HEK293 cell model. PloS one 2012;7:e50750.3517621.
46.
Park HJ, Shabashvili D, Nekorchuk MD, Shyqyriu E, Jung JI, Ladd TB, Moore BD,
Felsenstein KM, Golde TE, Kim SH. Retention in endoplasmic reticulum 1 (RER1)
modulates amyloid-beta (Abeta) production by altering trafficking of gamma-secretase
and amyloid precursor protein (APP). The Journal of biological chemistry
2012;287:40629-40.3504776.
47.
Moore BD, Chakrabarty P, Levites Y, Kukar TL, Baine AM, Moroni T, Ladd TB, Das P,
Dickson DW, Golde TE. Overlapping profiles of Abeta peptides in the Alzheimer's disease
and pathological aging brains. Alzheimer's research & therapy 2012;4:18.3506932.
48.
Liu Y, Zhang W, Li L, Salvador LA, Chen T, Chen W, Felsenstein KM, Ladd TB, Price AR,
Golde TE, He J, Xu Y, Li Y, Luesch H. Cyanobacterial peptides as a prototype for the
design of potent beta-secretase inhibitors and the development of selective chemical
probes for other aspartic proteases. Journal of medicinal chemistry 2012;55:10749-65.
49.
Harbut MB, Patel BA, Yeung BK, McNamara CW, Bright AT, Ballard J, Supek F, Golde TE,
Winzeler EA, Diagana TT, Greenbaum DC. Targeting the ERAD pathway via inhibition of
signal peptide peptidase for antiparasitic therapeutic design. Proceedings of the
National Academy of Sciences of the United States of America 2012;109:2148691.3535666.
50.
Hanna A, Iremonger K, Das P, Dickson D, Golde T, Janus C. Age-related increase in
amyloid plaque burden is associated with impairment in conditioned fear memory in
CRND8 mouse model of amyloidosis. Alzheimer's research & therapy
2012;4:21.3506935.
51.
Gu JW, Rizzo P, Pannuti A, Golde T, Osborne B, Miele L. Notch signals in the endothelium
15
CV Todd Eliot Golde, M.D., Ph.D. 2014
and cancer "stem-like" cells: opportunities for cancer therapy. Vascular cell
2012;4:7.3348040.
52.
Golde TE, Ran Y, Felsenstein KM. Shifting a complex debate on gamma-secretase
cleavage and Alzheimer's disease. The EMBO journal 2012;31:2237-9.3364746.
53.
Galasko D, Golde T, Wilcock G. Recent Alzheimer's disease research highlights.
Alzheimer's research & therapy 2012;4:14.3506929.
54.
Das P, Verbeeck C, Minter L, Chakrabarty P, Felsenstein K, Kukar T, Maharvi G, Fauq A,
Osborne BA, Golde TE. Transient pharmacologic lowering of Abeta production prior to
deposition results in sustained reduction of amyloid plaque pathology. Molecular
neurodegeneration 2012;7:39.3477045.
55.
Chu J, Giannopoulos PF, Ceballos-Diaz C, Golde TE, Pratico D. 5-Lipoxygenase gene
transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of
Alzheimer disease. Annals of neurology 2012;72:442-54.3464917.
56.
Chu J, Giannopoulos PF, Ceballos-Diaz C, Golde TE, Pratico D. Adeno-associated virusmediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP
mice. Molecular neurodegeneration 2012;7:1.3277480.
57.
Chen Y, Huang X, Zhang YW, Rockenstein E, Bu G, Golde TE, Masliah E, Xu H. Alzheimer's
beta-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of betaamyloid. The Journal of neuroscience : the official journal of the Society for
Neuroscience 2012;32:11390-5.3446780.
58.
Chakrabarty P, Tianbai L, Herring A, Ceballos-Diaz C, Das P, Golde TE. Hippocampal
expression of murine IL-4 results in exacerbation of amyloid deposition. Molecular
neurodegeneration 2012;7:36.3441281.
59.
Cao L, Schrank BR, Rodriguez S, Benz EG, Moulia TW, Rickenbacher GT, Gomez AC,
Levites Y, Edwards SR, Golde TE, Hyman BT, Barnea G, Albers MW. Abeta alters the
connectivity of olfactory neurons in the absence of amyloid plaques in vivo. Nature
communications 2012;3:1009.3529477.
60.
Cai J, Qi X, Kociok N, Skosyrski S, Emilio A, Ruan Q, Han S, Liu L, Chen Z, Bowes Rickman
C, Golde T, Grant MB, Saftig P, Serneels L, de Strooper B, Joussen AM, Boulton ME. betaSecretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and
accumulation of age pigment. EMBO molecular medicine 2012;4:980-91.3491829.
61.
Zhang Y, Zhen Y, Dong Y, Xu Z, Yue Y, Golde TE, Tanzi RE, Moir RD, Xie Z. Anesthetic
propofol attenuates the isoflurane-induced caspase-3 activation and Abeta
oligomerization. PloS one 2011;6:e27019.3206055.
62.
Wang A, Das P, Switzer RC, 3rd, Golde TE, Jankowsky JL. Robust amyloid clearance in a
mouse model of Alzheimer's disease provides novel insights into the mechanism of
16
CV Todd Eliot Golde, M.D., Ph.D. 2014
amyloid-beta immunotherapy. The Journal of neuroscience : the official journal of the
Society for Neuroscience 2011;31:4124-36.3074951.
63.
Sagi SA, Lessard CB, Winden KD, Maruyama H, Koo JC, Weggen S, Kukar TL, Golde TE,
Koo EH. Substrate sequence influences gamma-secretase modulator activity, role of the
transmembrane domain of the amyloid precursor protein. The Journal of biological
chemistry 2011;286:39794-803.3220583.
64.
Kukar TL, Ladd TB, Robertson P, Pintchovski SA, Moore B, Bann MA, Ren Z, Jansen-West
K, Malphrus K, Eggert S, Maruyama H, Cottrell BA, Das P, Basi GS, Koo EH, Golde TE.
Lysine 624 of the amyloid precursor protein (APP) is a critical determinant of amyloid
beta peptide length: support for a sequential model of gamma-secretase
intramembrane proteolysis and regulation by the amyloid beta precursor protein (APP)
juxtamembrane region. The Journal of biological chemistry 2011;286:3980412.3220543.
65.
Golde TE, Schneider LS, Koo EH. Anti-abeta therapeutics in Alzheimer's disease: the
need for a paradigm shift. Neuron 2011;69:203-13.3058906.
66.
Golde TE, Lamb BT, Galasko D. Right sizing funding for Alzheimer's disease. Alzheimer's
research & therapy 2011;3:17.3226306.
67.
Daily JL, Nash K, Jinwal U, Golde T, Rogers J, Peters MM, Burdine RD, Dickey C, Banko JL,
Weeber EJ. Adeno-associated virus-mediated rescue of the cognitive defects in a mouse
model for Angelman syndrome. PloS one 2011;6:e27221.3235088.
68.
Chakrabarty P, Herring A, Ceballos-Diaz C, Das P, Golde TE. Hippocampal expression of
murine TNFalpha results in attenuation of amyloid deposition in vivo. Molecular
neurodegeneration 2011;6:16.3050766.
69.
Chakrabarty P, Ceballos-Diaz C, Lin WL, Beccard A, Jansen-West K, McFarland NR, Janus
C, Dickson D, Das P, Golde TE. Interferon-gamma induces progressive nigrostriatal
degeneration and basal ganglia calcification. Nature neuroscience 2011;14:6946.3780582.
70.
Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, Miele L. Targeting Notch to
target cancer stem cells. Clinical cancer research : an official journal of the American
Association for Cancer Research 2010;16:3141-52.3008160.
71.
Meckler X, Roseman J, Das P, Cheng H, Pei S, Keat M, Kassarjian B, Golde TE, Parent AT,
Thinakaran G. Reduced Alzheimer's disease ss-amyloid deposition in transgenic mice
expressing S-palmitoylation-deficient APH1aL and nicastrin. The Journal of neuroscience
: the official journal of the Society for Neuroscience 2010;30:16160-9.2999009.
72.
Lewis J, Golde TE. Sorting out frontotemporal dementia? Neuron 2010;68:601-3.
73.
Grudzien P, Lo S, Albain KS, Robinson P, Rajan P, Strack PR, Golde TE, Miele L, Foreman
17
CV Todd Eliot Golde, M.D., Ph.D. 2014
KE. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells
and prevents mammosphere formation. Anticancer research 2010;30:3853-67.
74.
Golde TE, Petrucelli L, Lewis J. Targeting Abeta and tau in Alzheimer's disease, an early
interim report. Experimental neurology 2010;223:252-66.2864363
75.
De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in
Alzheimer disease. Nature reviews Neurology 2010;6:99-107.2879045
76.
Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, Zubair
AC, Dickson D, Golde TE, Das P. Massive gliosis induced by interleukin-6 suppresses
Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid
deposition. FASEB journal : official publication of the Federation of American Societies
for Experimental Biology 2010;24:548-59.3083918
77.
Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, Das P. IFNgamma promotes complement expression and attenuates amyloid plaque deposition in
amyloid beta precursor protein transgenic mice. Journal of immunology 2010;184:533343.3798002
78.
Carty N, Lee D, Dickey C, Ceballos-Diaz C, Jansen-West K, Golde TE, Gordon MN, Morgan
D, Nash K. Convection-enhanced delivery and systemic mannitol increase gene product
distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse
brain. Journal of neuroscience methods 2010;194:144-53.2995441
79.
Abisambra JF, Blair LJ, Hill SE, Jones JR, Kraft C, Rogers J, Koren J, 3rd, Jinwal UK, Lawson
L, Johnson AG, Wilcock D, O'Leary JC, Jansen-West K, Muschol M, Golde TE, Weeber EJ,
Banko J, Dickey CA. Phosphorylation dynamics regulate Hsp27-mediated rescue of
neuronal plasticity deficits in tau transgenic mice. The Journal of neuroscience : the
official journal of the Society for Neuroscience 2010;30:15374-82.3073547
80.
Zhang YJ, Xu YF, Cook C, Gendron TF, Roettges P, Link CD, Lin WL, Tong J, CastanedesCasey M, Ash P, Gass J, Rangachari V, Buratti E, Baralle F, Golde TE, Dickson DW,
Petrucelli L. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity.
Proceedings of the National Academy of Sciences of the United States of America
2009;106:7607-12.2671323
81.
Sun HS, Jackson MF, Martin LJ, Jansen K, Teves L, Cui H, Kiyonaka S, Mori Y, Jones M,
Forder JP, Golde TE, Orser BA, Macdonald JF, Tymianski M. Suppression of hippocampal
TRPM7 protein prevents delayed neuronal death in brain ischemia. Nature neuroscience
2009;12:1300-7
82.
Sudol KL, Mastrangelo MA, Narrow WC, Frazer ME, Levites YR, Golde TE, Federoff HJ,
Bowers WJ. Generating differentially targeted amyloid-beta specific intrabodies as a
passive vaccination strategy for Alzheimer's disease. Molecular therapy : the journal of
the American Society of Gene Therapy 2009;17:2031-40.2788047
18
CV Todd Eliot Golde, M.D., Ph.D. 2014
83.
Sala Frigerio C, Kukar TL, Fauq A, Engel PC, Golde TE, Walsh DM. An NSAID-like
compound, FT-9, preferentially inhibits gamma-secretase cleavage of the amyloid
precursor protein compared to its effect on amyloid precursor-like protein 1.
Biochemistry 2009;48:10894-904
84.
Rizzo P, Osipo C, Pannuti A, Golde T, Osborne B, Miele L. Targeting Notch signaling crosstalk with estrogen receptor and ErbB-2 in breast cancer. Advances in enzyme regulation
2009;49:134-41
85.
Rahimi N, Golde TE, Meyer RD. Identification of ligand-induced proteolytic cleavage and
ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells. Cancer research
2009;69:2607-14.2674781
86.
Parvanova I, Epiphanio S, Fauq A, Golde TE, Prudencio M, Mota MM. A small molecule
inhibitor of signal peptide peptidase inhibits Plasmodium development in the liver and
decreases malaria severity. PloS one 2009;4:e5078.2659798
87.
McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, Das P, Golde TE,
LaFerla FM, Oddo S, Blesch A, Tansey MG. Inhibition of soluble TNF signaling in a mouse
model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology.
Neurobiology of disease 2009;34:163-77.2948857
88.
Joshi I, Minter LM, Telfer J, Demarest RM, Capobianco AJ, Aster JC, Sicinski P, Fauq A,
Golde TE, Osborne BA. Notch signaling mediates G1/S cell-cycle progression in T cells via
cyclin D3 and its dependent kinases. Blood 2009;113:1689-98.2647664
89.
Golde TE, Wolfe MS, Greenbaum DC. Signal peptide peptidases: a family of
intramembrane-cleaving proteases that cleave type 2 transmembrane proteins.
Seminars in cell & developmental biology 2009;20:225-30
90.
Golde TE, Petrucelli L. "What kills neurons in neurodegenerative diseases?", a review
series in an open access journal. Molecular neurodegeneration 2009;4:7.2644306
91.
Golde TE, Miller VM. Proteinopathy-induced neuronal senescence: a hypothesis for
brain failure in Alzheimer's and other neurodegenerative diseases. Alzheimer's research
& therapy 2009;1:5.2874257
92.
Golde TE, Kukar TL. Medicine. Avoiding unintended toxicity. Science 2009;324:603-4
93.
Golde TE, Das P, Levites Y. Quantitative and mechanistic studies of Abeta
immunotherapy. CNS & neurological disorders drug targets 2009;8:31-49
94.
Golde TE. The therapeutic importance of understanding mechanisms of neuronal cell
death in neurodegenerative disease. Molecular neurodegeneration 2009;4:8.2644308
95.
Garcia-Alloza M, Subramanian M, Thyssen D, Borrelli LA, Fauq A, Das P, Golde TE,
Hyman BT, Bacskai BJ. Existing plaques and neuritic abnormalities in APP:PS1 mice are
19
CV Todd Eliot Golde, M.D., Ph.D. 2014
not affected by administration of the gamma-secretase inhibitor LY-411575. Molecular
neurodegeneration 2009;4:19.2687427
96.
Donnelly A, Galasko D, Golde T, Mulvany F, Wilcock G. Welcome to Alzheimer's research
& therapy. Alzheimer's research & therapy 2009;1:1.2719106
97.
Cho OH, Shin HM, Miele L, Golde TE, Fauq A, Minter LM, Osborne BA. Notch regulates
cytolytic effector function in CD8+ T cells. Journal of immunology 2009;182:3380-9
98.
Spilman P, Lessard P, Sattavat M, Bush C, Tousseyn T, Huang EJ, Giles K, Golde T, Das P,
Fauq A, Prusiner SB, Dearmond SJ. A gamma-secretase inhibitor and quinacrine reduce
prions and prevent dendritic degeneration in murine brains. Proceedings of the National
Academy of Sciences of the United States of America 2008;105:10595-600.2492499
99.
Samon JB, Champhekar A, Minter LM, Telfer JC, Miele L, Fauq A, Das P, Golde TE,
Osborne BA. Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the
maintenance of peripheral regulatory T cells. Blood 2008;112:1813-21.2518888
100.
Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch
signaling in cancer. Oncogene 2008;27:5124-31
101.
Palaga T, Buranaruk C, Rengpipat S, Fauq AH, Golde TE, Kaufmann SH, Osborne BA.
Notch signaling is activated by TLR stimulation and regulates macrophage functions.
European journal of immunology 2008;38:174-83
102.
Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L. ErbB-2 inhibition
activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Oncogene 2008;27:5019-32
103.
Osipo C, Golde TE, Osborne BA, Miele LA. Off the beaten pathway: the complex cross
talk between Notch and NF-kappaB. Laboratory investigation; a journal of technical
methods and pathology 2008;88:11-7
104.
Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, Healy B, Chapman R,
Welzel AT, Price RW, Moore B, Rangachari V, Cusack B, Eriksen J, Jansen-West K,
Verbeeck C, Yager D, Eckman C, Ye W, Sagi S, Cottrell BA, Torpey J, Rosenberry TL, Fauq
A, Wolfe MS, Schmidt B, Walsh DM, Koo EH, Golde TE. Substrate-targeting gammasecretase modulators. Nature 2008;453:925-9.2678541
105.
Kukar T, Golde TE. Possible mechanisms of action of NSAIDs and related compounds
that modulate gamma-secretase cleavage. Current topics in medicinal chemistry
2008;8:47-53.2740624
106.
Kim J, Miller VM, Levites Y, West KJ, Zwizinski CW, Moore BD, Troendle FJ, Bann M,
Verbeeck C, Price RW, Smithson L, Sonoda L, Wagg K, Rangachari V, Zou F, Younkin SG,
Graff-Radford N, Dickson D, Rosenberry T, Golde TE. BRI2 (ITM2b) inhibits Abeta
deposition in vivo. The Journal of neuroscience : the official journal of the Society for
20
CV Todd Eliot Golde, M.D., Ph.D. 2014
Neuroscience 2008;28:6030-6.2586000
107.
Jiang P, Ko LW, Jansen KR, Golde TE, Yen SH. Using leucine zipper to facilitate alphasynuclein assembly. FASEB journal : official publication of the Federation of American
Societies for Experimental Biology 2008;22:3165-74.2518257
108.
Czirr E, Cottrell BA, Leuchtenberger S, Kukar T, Ladd TB, Esselmann H, Paul S, Schubenel
R, Torpey JW, Pietrzik CU, Golde TE, Wiltfang J, Baumann K, Koo EH, Weggen S.
Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase.
The Journal of biological chemistry 2008;283:17049-54
109.
Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR,
Bartfai T. Transthyretin protects Alzheimer's mice from the behavioral and biochemical
effects of Abeta toxicity. Proceedings of the National Academy of Sciences of the United
States of America 2008;105:2681-6.2268196
110.
Ostrowski SM, Wilkinson BL, Golde TE, Landreth G. Statins reduce amyloid-beta
production through inhibition of protein isoprenylation. The Journal of biological
chemistry 2007;282:26832-44
111.
Li T, Wen H, Brayton C, Das P, Smithson LA, Fauq A, Fan X, Crain BJ, Price DL, Golde TE,
Eberhart CG, Wong PC. Epidermal growth factor receptor and notch pathways
participate in the tumor suppressor function of gamma-secretase. The Journal of
biological chemistry 2007;282:32264-73
112.
Lawlor PA, Bland RJ, Das P, Price RW, Holloway V, Smithson L, Dicker BL, During MJ,
Young D, Golde TE. Novel rat Alzheimer's disease models based on AAV-mediated gene
transfer to selectively increase hippocampal Abeta levels. Molecular neurodegeneration
2007;2:11.1906777
113.
Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP, Koo EH, Golde TE, Nicolle MM.
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic
amyloid precursor protein mice. BMC neuroscience 2007;8:54.1948891
114.
Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T,
McGowan E. Abeta40 inhibits amyloid deposition in vivo. The Journal of neuroscience :
the official journal of the Society for Neuroscience 2007;27:627-33
115.
Golde TE. The pathogenesis of Alzheimer's disease and the role of Abeta42. CNS
spectrums 2007;12:4-6
116.
Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, Mather G, Laughlin
M, Zavitz KH, Swabb E, Golde TE, Murphy MP, Koo EH. Safety, tolerability,
pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in
healthy elderly individuals. Alzheimer disease and associated disorders 2007;21:292-9
117.
Fauq AH, Simpson K, Maharvi GM, Golde T, Das P. A multigram chemical synthesis of the
21
CV Todd Eliot Golde, M.D., Ph.D. 2014
gamma-secretase inhibitor LY411575 and its diastereoisomers. Bioorganic & medicinal
chemistry letters 2007;17:6392-5.2962444
118.
Curry CL, Reed LL, Broude E, Golde TE, Miele L, Foreman KE. Notch inhibition in Kaposi's
sarcoma tumor cells leads to mitotic catastrophe through nuclear factor-kappaB
signaling. Molecular cancer therapeutics 2007;6:1983-92
119.
Wang J, Beher D, Nyborg AC, Shearman MS, Golde TE, Goate A. C-terminal PAL motif of
presenilin and presenilin homologues required for normal active site conformation.
Journal of neurochemistry 2006;96:218-27
120.
Shin HM, Minter LM, Cho OH, Gottipati S, Fauq AH, Golde TE, Sonenshein GE, Osborne
BA. Notch1 augments NF-kappaB activity by facilitating its nuclear retention. The EMBO
journal 2006;25:129-38.1356346
121.
Sato T, Nyborg AC, Iwata N, Diehl TS, Saido TC, Golde TE, Wolfe MS. Signal peptide
peptidase: biochemical properties and modulation by nonsteroidal antiinflammatory
drugs. Biochemistry 2006;45:8649-56
122.
Nyborg AC, Ladd TB, Zwizinski CW, Lah JJ, Golde TE. Sortilin, SorCS1b, and SorLA Vps10p
sorting receptors, are novel gamma-secretase substrates. Molecular neurodegeneration
2006;1:3.1513133
123.
Nyborg AC, Ladd TB, Jansen K, Kukar T, Golde TE. Intramembrane proteolytic cleavage
by human signal peptide peptidase like 3 and malaria signal peptide peptidase. FASEB
journal : official publication of the Federation of American Societies for Experimental
Biology 2006;20:1671-9
124.
Nyborg AC, Herl L, Berezovska O, Thomas AV, Ladd TB, Jansen K, Hyman BT, Golde TE.
Signal peptide peptidase (SPP) dimer formation as assessed by fluorescence lifetime
imaging microscopy (FLIM) in intact cells. Molecular neurodegeneration
2006;1:16.1654158
125.
Nguyen JH, Yamamoto S, Steers J, Sevlever D, Lin W, Shimojima N, Castanedes-Casey M,
Genco P, Golde T, Richelson E, Dickson D, McKinney M, Eckman CB. Matrix
metalloproteinase-9 contributes to brain extravasation and edema in fulminant hepatic
failure mice. Journal of hepatology 2006;44:1105-14.2667678
126.
Murphy MP, Golde TE. Inclusion-body myositis and Alzheimer disease: two sides of the
same coin, or different currencies altogether? Neurology 2006;66:S65-8
127.
Miele L, Golde T, Osborne B. Notch signaling in cancer. Current molecular medicine
2006;6:905-18
128.
Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR, Kim J, McGowan E, Reed
DK, Rosenberry TL, Das P, Golde TE. Insights into the mechanisms of action of anti-Abeta
antibodies in Alzheimer's disease mouse models. FASEB journal : official publication of
22
CV Todd Eliot Golde, M.D., Ph.D. 2014
the Federation of American Societies for Experimental Biology 2006;20:2576-8
129.
Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, Das P, Golde TE. Intracranial
adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and
amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid
precursor protein mice. The Journal of neuroscience : the official journal of the Society
for Neuroscience 2006;26:11923-8
130.
Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde
TE. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an
Alzheimer disease mouse model. The Journal of clinical investigation 2006;116:193201.1307561
131.
Leuchtenberger S, Kummer MP, Kukar T, Czirr E, Teusch N, Sagi SA, Berdeaux R, Pietrzik
CU, Ladd TB, Golde TE, Koo EH, Weggen S. Inhibitors of Rho-kinase modulate amyloidbeta (Abeta) secretion but lack selectivity for Abeta42. Journal of neurochemistry
2006;96:355-65
132.
Klein RL, Dayton RD, Leidenheimer NJ, Jansen K, Golde TE, Zweig RM. Efficient neuronal
gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;13:51727.2987642
133.
Herl L, Lleo A, Thomas AV, Nyborg AC, Jansen K, Golde TE, Hyman BT, Berezovska O.
Detection of presenilin-1 homodimer formation in intact cells using fluorescent lifetime
imaging microscopy. Biochemical and biophysical research communications
2006;340:668-74
134.
Golde TE, Dickson D, Hutton M. Filling the gaps in the abeta cascade hypothesis of
Alzheimer's disease. Current Alzheimer research 2006;3:421-30
135.
Golde TE. Disease modifying therapy for AD? Journal of neurochemistry 2006;99:689707
136.
Das P, Smithson LA, Price RW, Holloway VM, Levites Y, Chakrabarty P, Golde TE.
Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice
and does not alter efficacy following Abeta immunotherapy. Journal of
neuroinflammation 2006;3:17.1559596
137.
Das P, Golde T. Dysfunction of TGF-beta signaling in Alzheimer's disease. The Journal of
clinical investigation 2006;116:2855-7.1626134
138.
Boeve BF, Baker M, Dickson DW, Parisi JE, Giannini C, Josephs KA, Hutton M, PickeringBrown SM, Rademakers R, Tang-Wai D, Jack CR, Jr., Kantarci K, Shiung MM, Golde T,
Smith GE, Geda YE, Knopman DS, Petersen RC. Frontotemporal dementia and
parkinsonism associated with the IVS1+1G->A mutation in progranulin: a
23
CV Todd Eliot Golde, M.D., Ph.D. 2014
clinicopathologic study. Brain : a journal of neurology 2006;129:3103-14
139.
Minter LM, Turley DM, Das P, Shin HM, Joshi I, Lawlor RG, Cho OH, Palaga T, Gottipati S,
Telfer JC, Kostura L, Fauq AH, Simpson K, Such KA, Miele L, Golde TE, Miller SD, Osborne
BA. Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization
by preventing Notch upregulation of Tbx21. Nature immunology 2005;6:680-8
140.
McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J,
Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton
M, Hardy J, Golde T. Abeta42 is essential for parenchymal and vascular amyloid
deposition in mice. Neuron 2005;47:191-9.1373682
141.
Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R,
Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, Fauq A, Koo EH, Golde TE.
Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42
production. Nature medicine 2005;11:545-50
142.
Golde TE, Janus C. Homing in on intracellular Abeta? Neuron 2005;45:639-42
143.
Golde TE, Bacskai BJ. Bringing amyloid into focus. Nature biotechnology 2005;23:552-4
144.
Golde TE. The Abeta hypothesis: leading us to rationally-designed therapeutic strategies
for the treatment or prevention of Alzheimer disease. Brain pathology 2005;15:84-7
145.
Curry CL, Reed LL, Golde TE, Miele L, Nickoloff BJ, Foreman KE. Gamma secretase
inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells.
Oncogene 2005;24:6333-44
146.
Nyborg AC, Kornilova AY, Jansen K, Ladd TB, Wolfe MS, Golde TE. Signal peptide
peptidase forms a homodimer that is labeled by an active site-directed gammasecretase inhibitor. The Journal of biological chemistry 2004;279:15153-60
147.
Nyborg AC, Jansen K, Ladd TB, Fauq A, Golde TE. A signal peptide peptidase (SPP)
reporter activity assay based on the cleavage of type II membrane protein substrates
provides further evidence for an inverted orientation of the SPP active site relative to
presenilin. The Journal of biological chemistry 2004;279:43148-56
148.
Akbari Y, Hitt BD, Murphy MP, Dagher NN, Tseng BP, Green KN, Golde TE, LaFerla FM.
Presenilin regulates capacitative calcium entry dependently and independently of
gamma-secretase activity. Biochemical and biophysical research communications
2004;322:1145-52
149.
Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, Golde TE, Koo EH. Evidence
that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by
direct modulation of gamma-secretase activity. The Journal of biological chemistry
2003;278:31831-7
24
CV Todd Eliot Golde, M.D., Ph.D. 2014
150.
Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH. Abeta42-lowering
nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid
precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular
domain. The Journal of biological chemistry 2003;278:30748-54
151.
Sagi SA, Weggen S, Eriksen J, Golde TE, Koo EH. The non-cyclooxygenase targets of nonsteroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated
receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42
production. The Journal of biological chemistry 2003;278:31825-30
152.
Ramsden M, Nyborg AC, Murphy MP, Chang L, Stanczyk FZ, Golde TE, Pike CJ. Androgens
modulate beta-amyloid levels in male rat brain. Journal of neurochemistry
2003;87:1052-5
153.
Piper SC, Amtul Z, Galinanes-Garcia L, Howard VG, Ziani-Cherif C, McLendon C, Rochette
MJ, Fauq A, Golde TE, Murphy MP. Peptide-based, irreversible inhibitors of gammasecretase activity. Biochemical and biophysical research communications 2003;305:52933
154.
Palaga T, Miele L, Golde TE, Osborne BA. TCR-mediated Notch signaling regulates
proliferation and IFN-gamma production in peripheral T cells. Journal of immunology
2003;171:3019-24
155.
Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R,
Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with
plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003;39:40921
156.
Murphy MP, Das P, Nyborg AC, Rochette MJ, Dodson MW, Loosbrock NM, Souder TM,
McLendon C, Merit SL, Piper SC, Jansen KR, Golde TE. Overexpression of nicastrin
increases Abeta production. FASEB journal : official publication of the Federation of
American Societies for Experimental Biology 2003;17:1138-40
157.
Martoglio B, Golde TE. Intramembrane-cleaving aspartic proteases and disease:
presenilins, signal peptide peptidase and their homologs. Human molecular genetics
2003;12 Spec No 2:R201-6
158.
Golde TE, Eckman CB. Physiologic and pathologic events mediated by intramembranous
and juxtamembranous proteolysis. Science's STKE : signal transduction knowledge
environment 2003;2003:RE4
159.
Golde TE. Alzheimer disease therapy: can the amyloid cascade be halted? The Journal of
clinical investigation 2003;111:11-8.151845
160.
Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW,
Zavitz KH, Koo EH, Golde TE. NSAIDs and enantiomers of flurbiprofen target gamma25
CV Todd Eliot Golde, M.D., Ph.D. 2014
secretase and lower Abeta 42 in vivo. The Journal of clinical investigation 2003;112:4409.166298
161.
Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE. Amyloid-beta
immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience
2003;23:8532-8
162.
Das P, Chapoval S, Howard V, David CS, Golde TE. Immune responses against Abeta1-42
in HLA class II transgenic mice: implications for Abeta1-42 immune-mediated therapies.
Neurobiology of aging 2003;24:969-76
163.
Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, Younkin LH,
Younkin SG, Golde TE. Cholesterol-dependent gamma-secretase activity in buoyant
cholesterol-rich membrane microdomains. Neurobiology of disease 2002;9:11-23
164.
Tang-Wai D, Lewis P, Boeve B, Hutton M, Golde T, Baker M, Hardy J, Michels V, Ivnik R,
Jack C, Petersen R. Familial frontotemporal dementia associated with a novel presenilin1 mutation. Dementia and geriatric cognitive disorders 2002;14:13-21
165.
Sugarman MC, Yamasaki TR, Oddo S, Echegoyen JC, Murphy MP, Golde TE, Jannatipour
M, Leissring MA, LaFerla FM. Inclusion body myositis-like phenotype induced by
transgenic overexpression of beta APP in skeletal muscle. Proceedings of the National
Academy of Sciences of the United States of America 2002;99:6334-9.122949
166.
Ponting CP, Hutton M, Nyborg A, Baker M, Jansen K, Golde TE. Identification of a novel
family of presenilin homologues. Human molecular genetics 2002;11:1037-44
167.
Murphy MP, Uljon SN, Golde TE, Wang R. FAD-linked mutations in presenilin 1 alter the
length of Abeta peptides derived from betaAPP transmembrane domain mutants.
Biochimica et biophysica acta 2002;1586:199-209
168.
Leissring MA, Murphy MP, Mead TR, Akbari Y, Sugarman MC, Jannatipour M, Anliker B,
Muller U, Saftig P, De Strooper B, Wolfe MS, Golde TE, LaFerla FM. A physiologic
signaling role for the gamma -secretase-derived intracellular fragment of APP.
Proceedings of the National Academy of Sciences of the United States of America
2002;99:4697-702.123710
169.
Golde TE. Inflammation takes on Alzheimer disease. Nature medicine 2002;8:936-8
170.
Das P, Golde TE. Open peer commentary regarding Abeta immunization and CNS
inflammation by Pasinetti et al. Neurobiology of aging 2002;23:671-4; discussion 83-4
171.
Amtul Z, Lewis PA, Piper S, Crook R, Baker M, Findlay K, Singleton A, Hogg M, Younkin L,
Younkin SG, Hardy J, Hutton M, Boeve BF, Tang-Wai D, Golde TE. A presenilin 1 mutation
associated with familial frontotemporal dementia inhibits gamma-secretase cleavage of
APP and notch. Neurobiology of disease 2002;9:269-73
26
CV Todd Eliot Golde, M.D., Ph.D. 2014
172.
Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy
MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. A subset of NSAIDs lower
amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001;414:2126
173.
Pinnix I, Musunuru U, Tun H, Sridharan A, Golde T, Eckman C, Ziani-Cherif C, Onstead L,
Sambamurti K. A novel gamma -secretase assay based on detection of the putative Cterminal fragment-gamma of amyloid beta protein precursor. The Journal of biological
chemistry 2001;276:481-7
174.
Palacino JJ, Murphy MP, Murayama O, Iwasaki K, Fujiwara M, Takashima A, Golde TE,
Wolozin B. Presenilin 1 regulates beta-catenin-mediated transcription in a glycogen
synthase kinase-3-independent fashion. The Journal of biological chemistry
2001;276:38563-9
175.
Ni CY, Murphy MP, Golde TE, Carpenter G. gamma -Secretase cleavage and nuclear
localization of ErbB-4 receptor tyrosine kinase. Science 2001;294:2179-81
176.
Mudher A, Chapman S, Richardson J, Asuni A, Gibb G, Pollard C, Killick R, Iqbal T,
Raymond L, Varndell I, Sheppard P, Makoff A, Gower E, Soden PE, Lewis P, Murphy M,
Golde TE, Rupniak HT, Anderton BH, Lovestone S. Dishevelled regulates the metabolism
of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and
c-Jun terminal kinase. The Journal of neuroscience : the official journal of the Society for
Neuroscience 2001;21:4987-95
177.
McPhie DL, Golde T, Eckman CB, Yager D, Brant JB, Neve RL. beta-Secretase cleavage of
the amyloid precursor protein mediates neuronal apoptosis caused by familial
Alzheimer's disease mutations. Brain research Molecular brain research 2001;97:103-13
178.
Lewis PA, Piper S, Baker M, Onstead L, Murphy MP, Hardy J, Wang R, McGowan E, Golde
TE. Expression of BRI-amyloid beta peptide fusion proteins: a novel method for specific
high-level expression of amyloid beta peptides. Biochimica et biophysica acta
2001;1537:58-62
179.
Haugabook SJ, Yager DM, Eckman EA, Golde TE, Younkin SG, Eckman CB. High
throughput screens for the identification of compounds that alter the accumulation of
the Alzheimer's amyloid beta peptide (Abeta). Journal of neuroscience methods
2001;108:171-9
180.
Haugabook SJ, Le T, Yager D, Zenk B, Healy BM, Eckman EA, Prada C, Younkin L, Murphy
P, Pinnix I, Onstead L, Sambamurti K, Golde TE, Dickson D, Younkin SG, Eckman CB.
Reduction of Abeta accumulation in the Tg2576 animal model of Alzheimer's disease
after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin.
FASEB journal : official publication of the Federation of American Societies for
Experimental Biology 2001;15:16-8
27
CV Todd Eliot Golde, M.D., Ph.D. 2014
181.
Golde TE, Younkin SG. Presenilins as therapeutic targets for the treatment of
Alzheimer's disease. Trends in molecular medicine 2001;7:264-9
182.
Golde TE, Eckman CB. Cholesterol modulation as an emerging strategy for the treatment
of Alzheimer's disease. Drug discovery today 2001;6:1049-55
183.
Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. Reduced effectiveness of Abeta142 immunization in APP transgenic mice with significant amyloid deposition.
Neurobiology of aging 2001;22:721-7
184.
Murphy MP, Wang R, Fraser PE, Fauq A, Golde TE. An empirical model of gammasecretase activity. Annals of the New York Academy of Sciences 2000;920:233-40
185.
Murphy MP, Uljon SN, Fraser PE, Fauq A, Lookingbill HA, Findlay KA, Smith TE, Lewis PA,
McLendon DC, Wang R, Golde TE. Presenilin 1 regulates pharmacologically distinct
gamma -secretase activities. Implications for the role of presenilin in gamma -secretase
cleavage. The Journal of biological chemistry 2000;275:26277-84
186.
McLendon C, Xin T, Ziani-Cherif C, Murphy MP, Findlay KA, Lewis PA, Pinnix I,
Sambamurti K, Wang R, Fauq A, Golde TE. Cell-free assays for gamma-secretase activity.
FASEB journal : official publication of the Federation of American Societies for
Experimental Biology 2000;14:2383-6
187.
Lewis PA, Perez-Tur J, Golde TE, Hardy J. The presenilin 1 C92S mutation increases abeta
42 production. Biochemical and biophysical research communications 2000;277:261-3
188.
Houlden H, Baker M, McGowan E, Lewis P, Hutton M, Crook R, Wood NW, Kumar-Singh
S, Geddes J, Swash M, Scaravilli F, Holton JL, Lashley T, Tomita T, Hashimoto T,
Verkkoniemi A, Kalimo H, Somer M, Paetau A, Martin JJ, Van Broeckhoven C, Golde T,
Hardy J, Haltia M, Revesz T. Variant Alzheimer's disease with spastic paraparesis and
cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high
amyloid-beta concentrations. Annals of neurology 2000;48:806-8
189.
Golde TE, Eckman CB, Younkin SG. Biochemical detection of Abeta isoforms: implications
for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochimica et
biophysica acta 2000;1502:172-87
190.
Rennert H, Golde T, Wilson RB, Spitalnik SL, Van Deerlin VM, Leonard DG. A novel, nonnested reverse-transcriptase polymerase chain reaction (RT-PCR) test for the detection
of the t(15;17) translocation: a comparative study of RT-PCR cytogenetics, and
fluorescence In situ hybridization. Molecular diagnosis : a journal devoted to the
understanding of human disease through the clinical application of molecular biology
1999;4:195-209
191.
Murphy MP, Hickman LJ, Eckman CB, Uljon SN, Wang R, Golde TE. gamma-Secretase,
evidence for multiple proteolytic activities and influence of membrane positioning of
28
CV Todd Eliot Golde, M.D., Ph.D. 2014
substrate on generation of amyloid beta peptides of varying length. The Journal of
biological chemistry 1999;274:11914-23
192.
Cook DG, Sung JC, Golde TE, Felsenstein KM, Wojczyk BS, Tanzi RE, Trojanowski JQ, Lee
VM, Doms RW. Expression and analysis of presenilin 1 in a human neuronal system:
localization in cell bodies and dendrites. Proceedings of the National Academy of
Sciences of the United States of America 1996;93:9223-8.38623
193.
Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Jr., Eckman C, Golde TE, Younkin SG. An
increased percentage of long amyloid beta protein secreted by familial amyloid beta
protein precursor (beta APP717) mutants. Science 1994;264:1336-40
194.
Nakamura T, Shoji M, Harigaya Y, Watanabe M, Hosoda K, Cheung TT, Shaffer LM, Golde
TE, Younkin LH, Younkin SG, et al. Amyloid beta protein levels in cerebrospinal fluid are
elevated in early-onset Alzheimer's disease. Annals of neurology 1994;36:903-11
195.
Wertkin AM, Turner RS, Pleasure SJ, Golde TE, Younkin SG, Trojanowski JQ, Lee VM.
Human neurons derived from a teratocarcinoma cell line express solely the 695-amino
acid amyloid precursor protein and produce intracellular beta-amyloid or A4 peptides.
Proceedings of the National Academy of Sciences of the United States of America
1993;90:9513-7.47599
196.
Kalaria RN, Golde T, Kroon SN, Perry G. Serine protease inhibitor antithrombin III and its
messenger RNA in the pathogenesis of Alzheimer's disease. The American journal of
pathology 1993;143:886-93.1887201
197.
Golde TE, Cai XD, Shoji M, Younkin SG. Production of amyloid beta protein from normal
amyloid beta-protein precursor (beta APP) and the mutated beta APPS linked to familial
Alzheimer's disease. Annals of the New York Academy of Sciences 1993;695:103-8
198.
Cai XD, Golde TE, Younkin SG. Release of excess amyloid beta protein from a mutant
amyloid beta protein precursor. Science 1993;259:514-6
199.
Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai XD, McKay DM, Tintner R,
Frangione B, et al. Production of the Alzheimer amyloid beta protein by normal
proteolytic processing. Science 1992;258:126-9
200.
Golde TE, Estus S, Younkin LH, Selkoe DJ, Younkin SG. Processing of the amyloid protein
precursor to potentially amyloidogenic derivatives. Science 1992;255:728-30
201.
Gillespie SL, Golde TE, Younkin SG. Secretory processing of the Alzheimer amyloid
beta/A4 protein precursor is increased by protein phosphorylation. Biochemical and
biophysical research communications 1992;187:1285-90
202.
Estus S, Golde TE, Younkin SG. Normal processing of the Alzheimer's disease amyloid
beta protein precursor generates potentially amyloidogenic carboxyl-terminal
derivatives. Annals of the New York Academy of Sciences 1992;674:138-48
29
CV Todd Eliot Golde, M.D., Ph.D. 2014
203.
Estus S, Golde TE, Kunishita T, Blades D, Lowery D, Eisen M, Usiak M, Qu XM, Tabira T,
Greenberg BD, et al. Potentially amyloidogenic, carboxyl-terminal derivatives of the
amyloid protein precursor. Science 1992;255:726-8
204.
Kalaria RN, Golde TE, Cohen ML, Younkin SG. Serum amyloid P in Alzheimer's disease.
Implications for dysfunction of the blood-brain barrier. Annals of the New York Academy
of Sciences 1991;640:145-8
205.
Palmert MR, Podlisny MB, Golde TE, Cohen ML, Kovacs DM, Tanzi RE, Gusella JF,
Whitehouse PJ, Witker DS, Oltersdorf T, et al. Analysis of the beta-amyloid protein
precursor of Alzheimer's disease: mRNAs and protein products. Advances in neurology
1990;51:181-4
206.
Golde TE, Estus S, Usiak M, Younkin LH, Younkin SG. Expression of beta amyloid protein
precursor mRNAs: recognition of a novel alternatively spliced form and quantitation in
Alzheimer's disease using PCR. Neuron 1990;4:253-67
207.
Palmert MR, Podlisny MB, Golde TE, Cohen ML, Kovacs DM, Tanzi RE, Gusella JF,
Whitehouse PJ, Witker DS, Oltersdorf T, et al. The beta amyloid protein precursor:
mRNAs, membrane-associated forms, and soluble derivatives. Progress in clinical and
biological research 1989;317:971-84
208.
Palmert MR, Golde TE, Cohen ML, Kovacs DM, Tanzi RE, Gusella JF, Usiak MF, Younkin
LH, Younkin SG. Amyloid protein precursor messenger RNAs: differential expression in
Alzheimer's disease. Science 1988;241:1080-4
209.
Osborne BA, Golde TE, Schwartz RL, Rudikoff S. Evolution of the IgA heavy chain gene in
the genus Mus. Genetics 1988;119:925-31.1203475
210.
Cohen ML, Golde TE, Usiak MF, Younkin LH, Younkin SG. In situ hybridization of nucleus
basalis neurons shows increased beta-amyloid mRNA in Alzheimer disease. Proceedings
of the National Academy of Sciences of the United States of America 1988;85:122731.279740
211.
Osborne BA, Golde TE, Schwartz RL, Rudikoff S. Evolution of the mouse IgA gene:
nucleotide sequence comparison of IgA in BALB/c and Mus pahari. Current topics in
microbiology and immunology 1986;127:141-8
Book Chapters:
30
CV Todd Eliot Golde, M.D., Ph.D. 2014
1.
Chakrabarty P, Das P and Golde TE. Current and Future Therapies for Alzheimer’s
disease. In: Protein Misfolding Diseases: Current and Emerging Principles and Therapies.
Part IV. Ed. M. Ramirez-Alvarado, JW Kelly and CM Dobson. John Wiley & Sons, Inc.
Hoboken, New Jersey. 2010:711-774. ISBN: 978-0-471-79928-3.
2.
Golde TE. Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease.
In: The Dementias 2 Blue Books of Neurology Series, Volume 30. Ed. Growdon, J and
Rossor M. Elsevier. Philadelphia, PA. 2007:1-29.
3.
Golde TE, Zwizinski C, and Nyborg A. Signal peptide peptidases. Intramembrane Cleaving
Proteases in Biology and Disease series. Eds. Hopper, N and Ledeckel U. Springer.
Dordrecht, The Netherlands. 2007:17-30.
4.
Golde TE and Murphy MP. Aβ metabolism in Cholesterol Enriched Membranes. In Aβ
Metabolism and Alzheimer's Disease. Ed. Saido, T.C. Landes Bioscience. Austin, TX.
2003:58-62.
5.
Golde, TE and Younkin SG. Processing of the amyloid ß protein precursor. In:
Neuroscience Perspectives: Neurofibrillary Tangles and Amyloid Precursor Protein in
Alzheimer's Disease. eds. Goate, A and Ashall, F. Academic Press Ltd. San Diego, CA.
1995:115-143.
6.
Kalaria RN, Golde TE, Cohen ML, and Younkin SG. Serum amyloid P in Alzheimer's
disease, implications for dysfunction of the blood-brain barrier. In: Aging and
Alzheimer's disease, Sensory systems, neuronal growth, and neuronal metabolism. eds.
J.H. Growdon, Corkin, S., Ritter-Walker, E., and Wurtman, R.J. Annals of New York Acad.
Sciences, Vol. 640. New York. 1991: pp145-148.
7.
Golde TE, Palmert MR, Estus S, Usiak M, Siedlak SL, Perry G, Younkin LH, and Younkin
SG. The ß amyloid protein precursor: analysis of mRNAs in AD and control brains and of
soluble derivatives in human cerebrospinal fluid. In Molecular biology and genetics of
Alzheimer's disease. eds. T. Miyatake, D.J. Selkoe, and Y. Ihara. Elsevier Science
Publishers B.V. Amsterdam. 1990:pp. 137-147
8.
Palmert MR, Podlisny MB, Golde TE, Cohen ML, Kovacs DM, Tanzi RE, Gusella JF,
Whitehouse PJ, Witker DS, Oltersdorf T, Younkin LH, Selkoe DJ, and Younkin SG. The ß
amyloid protein precursor: mRNAs, membrane-associated forms and soluble derivatives
in Alzheimer's Disease and Related Disorders, eds. K. Iqbal, H.M. Wisniewski, and B.
Winblad, Alan R. Liss, Inc. New York 1989.
Abstracts Available on Request
31
CV Todd Eliot Golde, M.D., Ph.D. 2014
INVITED TALKS AND OTHER LECTURES
2015
07/14/15
06/10/15
05/27/15
05/14/15
05/09/15
04/16/15
03/22/15
02/13/15
01/08/15
01/07/15
01/23/15
01/20/15
01/17/15
2014
12/16/14
11/19/14
10/21/14
10/18/14
10/15/14
Can we target corticotropin releasing factor (CRF/CRH) for therapeutic benefit in
AD? AAIC, Alzheimer’s Association, Copenhagen Denmark.
A System Approach to Targeting Innate Immunity in AD. NIH AMP AD
Symposium, Washington, DC.
“The Alzheimer’s Disease Epidemic: Do We Have a Road Map to Combat It?”
Gainesville Elder Care Center, Gainesville, FL.
“The Alzheimer’s Disease Epidemic: Do We Have a Road Map to Combat It?”
Rotary Clubs of Southwest Florida, Captiva, FL.
Harnessing Innate Immunity to Treat Neurodegenerative Diseases.
4th
Venusberg Neuroinflammation Meeting, Bonn Germany.
“Harnessing Innate Immunity to Treat Neurodegenerative Diseases” University of
Chicago, Department of Neuroscience, Chicago, IL.
“Harnessing innate immunity to treat neurodegenerative diseases” AD/PD 2015,
Nice, France.
“The Alzheimer’s Disease Epidemic: Do We Have a Road Map to Combat It?”
Community Coalition for Older Adults, Gainesville, FL.
“Using rAAV vectors to manipulate phenotypes in preclinical neurodegenerative
disease models” AAV Data Blitz UF COM, Gainesville, FL.
“PSP: What We Know Today and Future Directions” Southeastern PSP
Symposium, Gainesville, FL.
“Alzheimer’s Disease: An overview of the field” Breakthroughs in Neurology:
Translating Today’s Discoveries into Tomorrow’s Clinics. American Academy of
Neurology. Phoenix, Arizona.
“Curbing the Alzheimer’s Disease Epidemic” UF Fundraiser, Orlando Country
Club, Orlando, FL.
Thinking Laterally About Neurodegenerative Proteinopathies. Plenary Talk, MCI
Symposium, Miami, FL.
“Using rAAV vectors to manipulate phenotypes in preclinical neurodegenerative
disease models” Mytonic Dystophy and Brian Symposium, Gainesville, FL.
“Thinking Laterally About Neurodegenerative Proteinopathies” Biogen IDECC,
Cambridge, MA.
“Can we Harness Innate Immunity to Treat or Prevent Neurodegenerative
Disease?” Burke Medical Research Institute, White Plains, NY.10/18/14
“Accelerating Preclinical Proof of Concept Studies for Disease Modification in
PSP” 2014 Annual CurePSP International Research Symposium. Baltimore, MD.
“Harnessing the Power of Modern Biomedical Discovery to Understand Disease
(and eventually to treat it): A roadmap derived from the study of Alzheimer’s
32
CV Todd Eliot Golde, M.D., Ph.D. 2014
09/30/14
09/18/14
09/04/14
07/30/14
07/28/14
07/14/14
05/02/14
02/05/14
2013
11/20/13
09/12/13
06/15/13
07/15/13
08/07/13
03/09/13
01/19/13
01/17/13
disease and other Neurodegenerative diseases” University of Florida
Undergraduates, Science for Life, Gainesville, FL.
“A system approach to targeting innate immunity in AD Year 1 Update” NIH AMP
AD meeting, Bethesda, MD.
“Novel Therapies for Neurodegenerative Disease: Lost in Translation?”
Committee for the Advancement of FDA Science (CAFDAS) Fall 2013
Distinguished Lecture Series of the Food and Drug Administration (FDA). Silver
Spring, Maryland.
“Towards Defining the Pathogenicity of Short Abeta” Data Blitz DNS Seminar and
“The Alzheimer’s disease Epidemic: Do We Have a Road Map to Combat It?”
Alzheimer’s Association, Walk to End AD kickoff event, Gainesville, FL.
“The Alzheimer’s Disease Epidemic: Do We Have a Road Map to Combat It?”
Orange and Blue, Tallahassee, FL.
“Harnessing Innate immunity to Treat or Prevent Neurodegenerative Disease”
Florida Brain Project Inaugural Symposium – Making Florida the State of Brain
Research, Tallahassee, Florida.
“Can we target corticotropin releasing factor (CRF) for therapeutic benefit in
AD?” Alzheimer’s Association International Conference, AAIC 2014. Copenhagen,
Denmark.
Neurology Year in Review plenary session, 66th Annual American Academy of
Neurology Meeting. Philadelphia, Pennsylvania.
“Innate Immune Modulatory Strategies for ALS and Alzheimer’s” within the
program of Strategies for Challenging CNS Targets – Case Study Examples of the
8th Annual drug Discovery for Neurodegeneration Conference: An Intensive
Course on Translating Research into Drugs. Miami, Florida.
Society for Neuroscience 2013, San Diego, California.
“Harnessing endogenous pathways and metabolites to treat or prevent
neurodegenerative disease” Molecular Neurodegeneration Basic biology and
disease pathways, Novotel Cannes Montfleury, Cannes, France.
“Protein Aggregation Spectrum Disorders” course within Neuroscience School of
Advanced Studies, Cortona, Italy.
Alzheimer’s Association International Conference, AAIC 2013. Boston,
Massachusetts.
“Can we harness innate immunity to treat Alzheimer’s Disease?” FBRI AD
Workshop, Banff 2013. Banff, Alberta, Canada
“Endogenous Modulators of Aβ Production” 11th International Conference on
Alzheimer’s & Parkinson’s Diseases (AD/PD 2011). Florence, Italy.
“Solving the Dilemma of Treatment versus Prevention Strategies for AD” Plenary
Talk, MCI Symposium, Miami Beach, Florida
“Towards Safe Enough Therapies for Alzheimer’s Disease Prevention?” Nathan
Kline Institute, Orangeburg, NY
33
CV Todd Eliot Golde, M.D., Ph.D. 2014
01/13/13
01/10/13:
“Searching in the Shadows for Novel Alzheimer's Disease Therapies” Department
of Pharmacology, University of Florida, Gainesville, FL
Lay Audience Talk. “The Alzheimer’s Disease Epidemic: Do We Have a Road Map
to Combat It?” Vero Beach, Florida
2012
11/16/12
09/13/12
09/12/12
05/18/12
05/08/12
“Towards Safe Enough Therapies for Alzheimer’s Disease Prevention?” McKnight
Brain Institute, University of Florida, Gainesville, Florida
“Disease Modifying Therapies For Neurodegenerative Proteinopathies: Lost in
Translation?” Whitney Laboratories, St. Augustine Florida
Lay Audience Talk. “The Alzheimer’s Disease Epidemic: Do We Have a Road Map
to Combat It?” Whitney Laboratories, St. Augustine Florida
“Identifying novel disease modifying strategies for the treatment and prevention
of AD” Mayo Clinic, Florida, Neuroscience Seminar Series. Jacksonville, FL.
“The Challenge of Developing Trigger Targeting Therapies for Alzheimer’s
Disease” University of Iowa Graduate Program in Neuroscience Seminar Series,
Iowa City, Iowa.
2011
12/02/11
11/29/11
10/19/11
09/17/11
03/11/11
“Paradigm shifts in Alzheimer's Disease” 7th Annual Predictive Health
Symposium by Emory University and Georgia Institute of Technology. Atlanta,
GA.
“Towards Novel Therapeutics for Alzheimer's Disease” Pennsylvania Institute on
Aging Visiting Scholars Seminar Series by University of Pennsylvania.
Philadelphia, PA.
“Alzheimer's Disease Therapeutics and the Treatment versus Prevention
Paradox” Columbia University, Taub Seminar Series. New York, NY.
“Lost in Translation: Trigger targeting therapies for Neurodegenerative Disease”
Plenary Talk, 4th Protein Misfolding and Neurological Disorders Meeting 2011,
Heron Island, Australia.
“Novel Insights into Inflammatory Mediators of Neurodegenerative Pathologies”
Plenary Speaker. 10th International Conference on Alzheimer’s & Parkinson’s
Diseases (AD/PD 2011). Barcelona, Spain.
2010
12/08/10
11/18/10
Lay Audience Talk “Tackling the4 AD epidemic” at the “I Still Do” exhibition at
Southeast Museum of Photography (SMP). Daytona State College, Daytona, FL.
“Alzheimer's Disease Therapeutics and the Treatment versus Prevention
Paradox” University of California, Irvine. UCI, Institute for Memory Impairments
and Neurological Disorders (MIND) seminar series. Irvine, CA.
34
CV Todd Eliot Golde, M.D., Ph.D. 2014
10/13/10
8/30/10
07/12/10
06/25/10
06/12/10
06/08/10
05/28/10
05/27/10
03/24/10
03/17/10
02/16/10
01/27/10
01/11/10
“Amyloid Based Vaccines and Intramembrane Cleaving Protease Inhibitors as
Therapeutics for Alzheimer’s disease and Malaria” Emerging Pathogens Institute
University of Florida, Gainesville, FL
“Alzheimer's Aging and the Senescence Response” Institute on Aging, University
of Florida, Gainesville, FL
“Obstacles to Translating Preclinical Advances into Successful Therapies For
Alzheimer's Disease.” Plenary Speaker. 2010 International Conference on
Alzheimer’s disease. Honolulu, Hawaii.
“Alzheimer's disease and reversing age related memory problems” Psychiatry
Grand Rounds, Department of Psychiatry, Gainesville, FL
“Alzheimer’s Disease: Models and Therapeutics” American Association of
Neuropathologists Annual Meeting. S.J. DeArmond Lecture: In recognition of
outstanding research in molecular pathogenesis of neurodegenerative disease
and translation to treatment. Philadelphia, PA.
“Rationale approaches and obstacles to targeting Aβ and Aβ aggregates in AD.”
CINP, Symposium on Neurodegeneration, Hong Kong, China.
“What mouse models can tell us about disease modifying therapy for
Alzheimer's disease?” Neuroscience Genentech, South San Francisco, CA.
“Preclinical Models and Therapeutics for Alzheimer's disease and other
Neurodegenerative Conditions” Gladstone Institute UCSF, San Francisco CA.
“Somatic Brain Transgenesis using rAAV vectors: Utility for Neurodegenerative
disease” PGTC, University of Florida, Department of Pediatrics. Gainesville FL.
“Disease Modifying Therapy for Alzheimer’s disease: Progress and Setbacks”
Department of Neuroscience, COM, University of Florida Research Night.
Gainesville FL.
“Translational Research in Alzheimer’s Disease and Other Neurodegenerative
Disorders” Science For Life Program HHMI University of Florida Undergraduates.
Gainesville FL.
“Disease Modifying Therapy for Alzheimer’s disease”Sanford/Burnham Medical
Research Institute at Lake Nona Seminar Series. Orlando, FL
“Preclinical Studies of Alzheimer's Disease and the Treatment versus Prevention
Paradox” Keystone Symposium, Copper Mountain, CO.
2009
11/19/09
08/26/09
08/04/09
07/12/09
“Targeting “Toxic” Aß Peptide (Aggregates) in Alzheimer's disease” Pathobiology
of Dementias Symposium, AGS meeting. Atlanta, GA.
“Targeting amyloid deposition in mice: the earlier the better.” Translational
Research in AD conference. Stockholm, Sweden.
“Towards Novel AD Therapies” Medical Grand Rounds Mayo Clinic Florida,
Jacksonville, Florida
“Alzheimer's Disease: Is it really Senescent Dementia?” Neurology Grand
Rounds, Mayo Clinic Florida.
35
CV Todd Eliot Golde, M.D., Ph.D. 2014
04/15/09
“Translating Basic Discovery in Alzheimer’s disease to the Clinic: Obstacles and
Successes.” International Conference on Teaching and Learning FCCJ.
Jacksonville, FL
2008
10/29/08
10/21/08
10/09/08
09/20/08
09/08/08
07/24/08
04/16/08
02/20/08
“Substrate Targeting GSMs.” Eibsee meeting on AD, Keynote Lecture. Eibsee,
Germany.
“Future Therapy for Alzheimer’s disease” Bioflorida 2008, Amelia Island, FL.
“Targeting Aß production and aggregation in AD” GCI Neurodegenerative
Disease Drug Discovery, Philadelphia, PA.
“Novel methods to target Aß production and aggregation in AD” UBC,
Vancouver, Canada.
“Alzheimer’s Disease Models and Therapeutics” University of Florida. Gainesville,
FL.
“Anti-Aß antibodies in Alzheimer's disease mouse models” ICAD, Chicago, IL.
“GSMs and BRI peptides that target Aß as AD Therapeutics” Elan Inc, San
Francisco, CA
“Amyloid Metabolism and Cognitive Impairment in Animals and Humans” MCI
Symposium, Miami Beach, FL.
2007
11/03/07
10/16/07
10/08/07
09/26/07
08/29/07
04/05/07
03/13/07
03/08/07
03/02/07
02/08/07
“BRI2 inhibits Amyloid Deposition”. Society for Neuroscience Annual Meeting.
San Diego, CA.
“Unraveling Alzheimer’s Disease” UTSW Department of Neuroscience, Dallas, TX.
“Small Molecule Modulators of Aß production and aggregation as AD
Therapeutics” MAPS. Philadelphia, PA.
“Substrate targeting by -secretase modulators.” The Notch Meeting Athens,
Greece.
“Aß42 in AD pathogenesis.” CME mini-symposium European Federation of
Neurological Societies - EFNS 2007 - in Brussels, Belgium.
“Modulating and Inhibiting Intramembrane Proteolysis” New York Academy of
Sciences. NY, NY.
“AD Models and Therapies” TGEN. Phoenix, Arizona.
“The Anti-amyloid Strategies Active and Passive” Dementia Symposium Mt. Sinai
SOM. NY, NY.
“Aß42 in AD pathogenesis” AAGP annual meeting. New Orleans, LA.
“Novel AD Models and Therapies” UCSD ADRC seminar series.
2006
36
CV Todd Eliot Golde, M.D., Ph.D. 2014
11/06/06
10/17/06
10/14/06
04/01/06
02/09/06
“Magic Bullets, Shotguns, or Cocktails to treat or Prevent AD? Alz100 meeting,
Tubingen, Germany.
“Disease Modifying therapies for Alzheimer’s Disease?” Sigma Lunch
Symposium. SFN, Atlanta, GA.
“Rapid in vivo Paradigms for Evaluating Candidate Death pathways in
Neurodegenerative Disease” Neurotoxicity Society Symposium. Emory
University, Atlanta, GA.
“Modeling and preventing Aß deposition in AD mouse models” Department of
Pharmacology, University of Pennsylvania.
“Disease Modifying therapies for Alzheimer’s Disease?” Medical Grand Rounds<
Mayo Clinic Florida, Jacksonville Florida
2004
12/02/04
06/21/04
04/16/04
03/08/04
“NSAIDS and AD”. CSHL Drug discovery for Neurodegenerative Disease
Symposium, Cold Spring Harbor, NY.
“Novel approaches to selective targeting of Aß42.” Novartis. Basel, Switzerland.
“Aß as a therapeutic target.” Eli Lilly, Indianapolis, IN
“Targeting Aß42.” NIH NINDS. Washington DC
2003
11/06/03
08/14/03
05/16/03
01/21/03
“NSAIDS, Abeta42 lowering and Alzheimer’s Disease.” National Parkinson’s
Foundation 8th International Symposium on Parkinson Research. New Orleans,
LA.
“Gamma-Secretase in Alzheimer’s Disease”. Ellison Medical Foundation/ Biology
of Aging Colloquium. Woods Hole, MA.
“Therapeutic Approaches to AD: Anti-amyloid Strategies.” American Geriatric
Society, Baltimore, Maryland.
“Secretases as therapeutic targets for the treatment or Prevention of
Alzheimer’s” Disease Vanderbilt University, Nashville, Tennessee.
2002
09/15/02
07/22/02
07/22/02
“Aβ42 as a Therapeutic target in AD” Grand Rounds, Mayo Clinic Jacksonville,
Jacksonville, FL
“The Cell Biology of -Secretase.” Symposium International Alzheimer’s
Conference, Stockholm, Sweden.
“Some NSAIDs Selectively Lower Aß42: Implications for AD”, Elan Satellite
Symposia on therapeutics for AD. International Conference on AD. Stockholm,
Sweden.
37
CV Todd Eliot Golde, M.D., Ph.D. 2014
07/20/02
06/21/02
05/12/02
04/15/02
03/27/02
03/20/02
01/03/02
“Effects of FDA-Approved NSAIDS on Aß Levels in APP Transgenic Mice.” NIA
sponsored satellite symposia from Epidemiology to Therapeutic Trials with Antiinflammatory Drugs in AD. Stockholm, Sweden.
“Presenilins as Therapeutic Targets for the treatment of Alzheimer's Disease.”
American Society for Neurochemistry. Symposia. Palm Beach, Florida.
“Evaluating Alzheimer’s Disease Therapeutic Strategies in Model Systems”
Genetics and Aging Institute. MGH, Boston, MA.
“Factors affecting Aß production”. Myriad Genetics, Salt Lake City, UT.
“Aß42 lowering agents Elan Pharmaceuticals”, San Francesco, CA.
“Aß42 lowering agents” Chiesi Pharmaceuticals Parma, Italy.
“Discovering and Evaluating Therapeutic Strategies for the treatment or
prevention of AD” In “Delivering the cures: Where are they?” Symposia Society
for Neuroscience Conference 2002 Orlando Florida.
2001
11/16/01
10/21/01
09/29/01
06/05/01
“Evaluating Therapeutic targets in AD using Model Systems. Scripps Clinic, La
Jolla CA”
“The Molecular neurobiology of Alzheimer’s disease.” PSP and AD research
retreat. Stowe School UK.
“Evaluating Therapeutic Targets in AD” Mayo Clinic Jacksonville ADRC Seminar
Series.
“Evaluating Therapeutic targets in AD” Dupont Pharmaceuticals.
2000
09/20/00”
05/16/00
05/11/00
05/04/00
02/20/00
“Therapeutic Strategies for the Treatment of Alzheimer's Disease”
“Are Presenilins -Secretase?” Washington University, Department of Neurology.
“γ-Secretases in AD” Mayo Clinic Jacksonville ADRC Seminar Series
“In vitro -Secretase assays” Pfizer, Inc Groton, CT
“Models of -secretase activity.” 9th annual International Study group on the
genetics of neurodegenerative disease, Zurich, Switzerland.
CONTRACTS AND GRANTS
Since 1997 I have been awarded over $15M dollars in extramural funding from the NIH, various
private foundations, and industry.
Active
Period: 04/01/2002-06/30/2016
Type: P01 AG020206 (Original and one competitive Renewal)
Todd E Golde PI Project 2 (E. Koo Overall PI)
38
CV Todd Eliot Golde, M.D., Ph.D. 2014
Title P01: NOVEL MECHANISMS OF NSAID ACTION IN ALZHEIMER DISEASE Project 2: TARGET
IDENTIFICATION AND MECHANISMS OF ACTIONS OF Y-SECRETASE MODULATORS
Agency: NIH/NIA
Funding Project 2:
2002-2007: Direct cost: $246,639/yr; indirect cost: $130,719/yr, Total funding over 5 years
to T. Golde $1,886,788
2009-2014: Direct cost: $318,443/yr; indirect cost: $148,705/yr, Total funding over 5 years
to T. Golde $2,335,740
2014-2015: Direct cost $306,884/yr.
2015-2016: Direct cost $336,016/yr.
Period 09/01/13- 06/30/18
R01AG046139-01
A system approach to targeting innate immunity in AD
T. Golde Contact PI (Younkin, Ertekin Taner Price MPI)
Agency NIH/NINDS
Direct Costs $~995,000/yr Total costs ~$1.9M/yr
Period: 09/20/13-08/31/2018
Type 1P01CA166009-01A1 OSBORNE
T. Golde PI Project 3 (B. Osborne Overall PI)
Title: P01 TARGETING MULTIPLE DISEASES THROUGH GAMMA SECRETASE
Agency: NIH/NCI
Funding Project 3: Direct cost: ~$200,000/yr
Period: 05/15/2014- 02/28/2019
Type: R01 AG18454 (original, 2 competitive Renewals, one supplement)
T. Golde PI
Title: IMMUNE-MEDIATED MECHANISMS UNDERLYING CNS ABETA CLEARANCE
Agency: NIH/NIA
Funding:
Years 1-3: $150,000/yr; indirect cost $79,500/yr
Years 4-6: Direct cost $175,0000/yr; indirect cost $94,500/yr
Years 7-11: Direct cost $202,950/yr; indirect cost $94,372/yr
Supplement Direct Costs $59,404; indirect Costs $29,702
Total funding for entire R01: $3,072,716
Period: 05/01/2015 – 04/30/2020
Type: T32 NS082168-01A1
T. Golde Co-Investigator
Title: INTERDISCIPLINARY TRAINING IN MOVEMENT DISORDERS AND NEURORESTORATION
Agency: NIH/NINDS
Funding: $0.00
39
CV Todd Eliot Golde, M.D., Ph.D. 2014
Completed
Period 07/1/13-06/31/15
MJFF Target Validation Program
T. Golde PI
IL-10 as a Therapeutic Target for PD
Agency: MJFF
Direct Costs Requested $200,000 Total Costs Requested $250,000
Period: 10/01/2010- 9/30/2014
Type: Ellison Medical Foundation Senior Scholar Award
T. Golde PI
Title Proteinopathy induced Neuronal Senescence and Inflammation
Agency: Ellison Medical Foundation
Funding Project 2:
Direct cost: $150,000/yr; indirect cost: $69,000yr, Total funding over 4 years to T. Golde
$876,000
Period: 01/01/2011-12/31/28/2014
Type: Thome Medical Foundation Award
T. Golde PI
Title: Anti-amyloid vaccines and human anti-amyloid antibodies.
Agency: Thome Medical Foundation
Funding: 227,272 direct/yr (includes subcontract to S. Dessain for $113,636), Total funding
for entire period $750,000
Period: 08/15/2000-02/28/2013
Type: R01 AG18454 (original, 2 competitive Renewals, one supplement)
T. Golde PI
Title: IMMUNE-MEDIATED MECHANISMS UNDERLYING CNS ABETA CLEARANCE
Agency: NIH/NIA
Funding:
Years 1-3: $150,000/yr; indirect cost $79,500/yr
Years 4-6: Direct cost $175,0000/yr; indirect cost $94,500/yr
Years 7-11: Direct cost $202,950/yr; indirect cost $94,372/yr
Supplement Direct Costs $59,404; indirect Costs $29,702
Total funding for entire R01: $3,072,716
A0 Competitive Renewal Submitted Scored 30 13% 3/13
Period: 03/01/2011-2/28/2014
Type: R21 AG035054
40
CV Todd Eliot Golde, M.D., Ph.D. 2014
T. Golde Co-I (Janus PI)
Title: Effects of Intracellular Targeted and FAD-linked Mutant Amyloid Betas
Agency: NIH/NIA
Funding: $102,500 direct/yr 1 123,000 direct year 2
Period: 9/1/2012-8/31/13
Type: ALSA Grant
T. Golde PI
Title: Neuroinflammation in ALS
Agency: ALSA
Funding: $80,000 direct
Period: 09/01/2012 to 08/31/2013
R01-EY018358-06
Project Title: Non-canonical VEGF receptor signaling regulates retinal neovascularization
Golde Co-I (Boulton PI)
Agency: NIH
Annual Direct Costs $250,000 Indirect $125,000
Period: 01/01/2010 to 2012
Type: Foundation Award
Todd E Golde PI
Title: Metlife Award
Agency: Metlife Foundation for Medical Research
Total funding: $100,000; Direct cost: $100,000; Indirect cost
Period: 07/15/2006-06/30/2011
Type: PO1 AG025531
T. Golde PI Project 1 (B. Osborne Overall PI)
Title: P01 TARGETING MULTIPLE DISEASES THROUGH GAMMA SECRETASE Project 1: Aβ
AND BEYOND: SECRETASE A DRUG TARGET FOR CNS DISEASE
Agency: NIH/NIA/NCI
Funding Project 1: Direct cost: $178,819/yr; Indirect cost: $83,150/yr, Total funding over 5
years to T. Golde $1,309,850
Period: 05/01/2009-04/30/2010
Type: NIH 5P50 AG016574
T. Golde Co-PI (R. Petersen PI P50, R. Rademakers PI Project 2)
Title: THE PGRN/TDP-43 AXIS IN ALZHEIMER’S DISEASE AND FTLD
Agency: NIH/NIA
Funding: To T. Golde Direct $25,000 Indirect $13,250
Period: 2008-2010
41
CV Todd Eliot Golde, M.D., Ph.D. 2014
Type Industry Sponsored Research
T. Golde. PI
Title: IN VIVO KNOCKDOWN OF BRAIN EXPRESSED GENES WITH AAV VECTORS.
Type: Sponsored Research Agreement
Source: Lundbeck Pharmaceuticals
Total funding: $513,240, T. Golde $182,000 direct/yr and $74,602/yr indirect
Period: 04/10/2000- 04/30/2010
Type: 5R01NS039072-08
Todd E Golde PI (M. Wolfe Harvard Co-I, 2004-08)
Title: GAMMA-SECRETASES IN ALZHEIMER'S DISEASE
Agency: NIH/NINDS
Funding: Years 2000-2002: Direct $200,000/yr Indirect $100,700/yr; Years 2004-08 to T.
Golde Direct $175,000/yr Indirect $92,750/yr; Total Funding to T. Golde $2,089,600
Period: 08/11/2009-06/30/2010
Type: R56-A1-081797-01
Role: T. Golde Co-PI (D. Greenbaum UPenn PI) Percent effort 2.5%
Title: PLASMODIUM SIGNAL PEPTIDE PEPTIDASE AS A NOVEL ANTIMALARIAL TARGET
Agency: NIH/NIAID
Funding: To T. Golde Direct $71,740 yr Indirect $38,022
Period: 08/01/2008-05/31/2009
T. Golde (Contact MPI), (E. Koo UCSD (MPI))
Title: ABETA42 ALTERING COMPOUNDS: MECHANISMS OF ACTION
Type: R01 AG029886
Agency: NIH/NIA
Funding: Total: $532,690 to T. Golde Direct $241,901, Indirect $128,208
(Replaced when P01 AG20206 was renewed)
Period: 2003-2008
Type: Sponsored Research Agreement
T. Golde PI
Title: DEVELOPMENT OF AN IMPROVED ABETA 42 LOWERING COMPOUND
Agency: Myriad Genetics
Total funding: $910,000, T. Golde $182,000 direct/yr
Period: 9/1/2007-8/31/2009
Type: Foundation Research Grant
T. Golde PI Percent effort
Title: ABETA42 LOWERING COMPOUNDS THAT BLOCK AB AGGREGATION AS NOVEL
THERAPEUTIC AGENTS FOR ALZHEIMER’S DISEASE
Agency: Coins for Alzheimer’s Research Trust (CART)
42
CV Todd Eliot Golde, M.D., Ph.D. 2014
Total funding: $250,000; Direct cost: $125,000/yr; Indirect cost: $0
Period: 09/30/2003 - 08/31/2007
Type: AG022595
Role: T. Golde Co-I (E. McGowan PI)
Title: TRANSGENIC MICE DEPOSITING INDIVIDUAL AB PEPTIDES
Agency: NIH/NIA
Funding: Total $1,238,200 Total to T. Golde $123,820) (Direct $20,500/yr Indirect $10,950)
Period: 09/30/2005 - 08/31/2007
Type: Zenith Award
T. Golde PI Percent effort 15%
Title: NOVEL MODELS OF AMYLOID DEPOSITION
Agency: Alzheimer’s Association
Funding: Total $250,000 Direct $112,500/yr Indirect $12,500/yr
Period: 2004-2005
Type Sponsored Research Agreement
T. Golde PI
Title: TESTING OF TEVA COMPOUNDS IN Tg2576 MICE.
Agency: TEVA
Total funding: $230,000; Direct cost: $161,000; Indirect cost: $69,000
Period: 2004-2006
Type: Florida Alzheimer’s Center Research Grant
T. Golde PI Percent effort
Title: “MODIFIED” AB PEPTIDES EFFECTS ON AD PATHOGENESIS.
Agency: FACR
Total funding: $331,654; Direct cost: $250,000; Indirect cost: $81,654
Period: 09/01/2002 - 08/31/2005
Type: AG021875
Todd E Golde PI (David Curiel UAB Co-I) Percent effort 10%
Title: IN SITU THERAPEUTIC ANTI-AB DELIVERY/ADENOVIRAL VECTORS
Agency: NIH/NINDS
Funding: Total $694,350 Total to T. Golde $313,611
Funding T. Golde Direct $104,537 Indirect $56,450
Period: 05/01/2000-04/30/2001
T. Golde PI (E. Richelson Co-I)
Title: PNA'S AS MODULATORS OF PRESENILIN EXPRESSION
Type: R03AG018060
Agency: NIH/NIA
43
CV Todd Eliot Golde, M.D., Ph.D. 2014
Total funding: $76,500
Direct $50,000 Indirect $26,500
Period: 05/01/2000-04/30/2001
NIH Pilot on ADRC P50
Role: T. Golde PI
Title: DEVELOPMENT OF A CLONED TRANSGENIC RAT MODEL OF AD. Mayo ADRC Agency:
NIH
Total funding: $30,000
Direct $19,607, Indirect $10,392.
Period: 09/30/1999 - 08/31/2002
T. Golde PI
Title: IDENTIFICATION OF NOVEL CELLULAR TARGETS FOR ANTI-A THERAPY.Type: IIRG
Agency: Alzheimer’s Association
Funding: Total $180,000 Direct $54,000/yr Indirect $6,000/yr
Period: 1998-2002
Type: New Scientist Award
T. Golde PI Title:
PRESENILINS AND - SECRETASE CLEAVAGE OF THE AMYLOID  PROTEIN PRECURSOR.
Agency: Ellison Medical Foundation
Total funding: $200,000; Direct cost: $50,000/yr
Period: 09/01/1997 - 08/31/2005
Type: Beeson Award Todd E Golde PI Percent effort 20%
Title: PROTEOLYTIC GENERATION OF THE AMYLOID ß PEPTIDE IN ALZHEIMER’S DISEASE. 3
years.
Agency: AFAR/John Hartford Foundation
Funding: Total $450,000, Direct $150,000/yr
Period: 09/30/1996- 08/31/1997
Type: Pilot
T. Golde PI Percent effort 5%
Title: TRANSPLANT MODELS OF ALZHEIMER’S DISEASE
Agency: Alzheimer’s Association
Funding: Total $26,730 Direct $2,970
.
Sponsor of Trainee Grants (Only NIH grants are listed, during their fellowships in my laboratory
Drs. Eriksen, Levites, Murphy, Das, and Kukar were awarded foundation grant):
Period 2002-2003
Trainee: Andrew Nyborg PhD postdoctoral fellow
44
CV Todd Eliot Golde, M.D., Ph.D. 2014
Type: NRSA Postdoctoral Fellowship F32 NS044734
Agency NIH/NINDS
Role: Mentor
Period 2009-2010
Trainee Thomas Kukar
Type: pathways K99/R00 NIH
Agency NIH/NIA
Funding $90,000/yr total
Role: Mentor for years 1-2 (now an independent assistant professor)
TEACHING, ADVISING AND/OR INSTRUCTIONAL ACCOMPLISHMENTS
Current Junior Faculty Mentorship
Kevin Felsenstein, PhD, Research Associate Professor of Neuroscience
Diego Rincon Limas, Assistant Professor of Neurology
Pedro Fernandez-Funez, Assistant Professor of Neurology
Paramita Chakrabarty PhD Associate Scientist
Yong Ran, Associate Scientist PhD
Michael Waters MD PhD, Assistant Professor of Neurology
Chris Janus, PhD, Research Assistant Professor of Neuroscience
Yona Levites, PhD, Research Assistant Professor of Neuroscience
Nikolaus McFarland MD PhD Assistant Professor of Neurology
Edgardo Rodriguez, PhD Assistant Professor of Pharmacology
Postdoctoral Fellows
2008-Current
2011-2013
2008-2012
2006-2010
2008-2009
2006-2010
2006-2008
2005-2006
2004-2006
2003-2008
2003-2006
2002-2003
2001-2005
Brenda Moore PhD
Hyo-Jin Park PhD (Biological Scientist, UF)
Wei Kuo, PhD (Returned to China)
Paramita Chakrabarty PhD (current position Research Asst Prof
U. Florida)
Cathy Andorfer PhD (Mayo Clinic)
Victor Miller PhD (unknown)
Criag Zwisinski PhD (unknown)
Rudi Hrncic MD (unknown)
Vallie Holloway, Ph.D. (current position Instructor FCCJ)
Thomas Kukar, Ph.D. (current position, Asst. Prof. Emory Univ.)
Yona Levites (current position Research Asst Prof U. Florida)
Zareen Amtul PhD (unknown)
Andrew Nyborg PhD (current position Industry Scientist)
45
CV Todd Eliot Golde, M.D., Ph.D. 2014
2001-2004
1999-2004
1997-2004
Jason Eriksen PhD (current position Asst. Prof, UT Houston)
Pritam Das PhD (current position Asst. Prof, Mayo Clinic)
M. Paul Murphy PhD (current position Asst. Prof, U. Kentucky)
MS/PhD/MD PhD Students
2015-current
2010-current
2011-current
2011-current
2011-2014
2011-2014
2006-2007
2002-2006
2002-2005
Kevin Strang
Keith Crosby (PhD)
Amanda Herring (PhD
Yuanjing Liu (PhD)
Amanda Sacino (MD PhD)
Joo In Jung
(PhD)
Becky Stodola (MS)
Jungsu Kim (PhD) Current position Asst. Prof Wash U Neurology
Hyun-Hee Kim (MS)
Thesis Committees
2012-current
2011-current
2011-current
2011-current
2010-current
2002-2006
2002-2005
2002-2004
2001-2004
1999-2002
1999-2000
1999-2001
Yuanjing Liu
Amanda Sacino (Chair)
Amanda Herring
Joo In Jung (Chair)
Keith Crosby
Jungsu Kim PhD (Chair)
Hyun-hee Kim M.S. (Chair)
Fanny Gonzalez de Chavez M.S.
William Hu MD PhD (current position Asst Prof Emory U)
Andrew West PhD (Current Asst Prof UAB)
Tian-Pei Xia PhD
Nilufer Tanner MD PhD (Current Asst Prof Mayo Clinic)
Summer Undergraduates
2006
2005
2004
2003
2001
2001
2000
1999
1999
1998
Rohit Raj
Maralyssa Bann (Med School JHU)
Shaun Prabhu
Shelton Wright
Sami Merit
Mark Dodson
Johnathan Malowitz
Matt Demming
Sylvie Thompson
Andrew West (Current Asst Prof UAB)
46
CV Todd Eliot Golde, M.D., Ph.D. 2014
British Undergraduates
2008-2009
2006-2007
2003-2004
2002-2003
2001-2002
2000-2002
1999-2000
Paul Robertson
Kayleigh Wagg
John Pooley
Jenny Beard
Laura Galinanes-Garcia
Sian Piper
Patrick Lewis (current position Asst. Prof., UCL, London)
Undergraduate Researchers
Since 2010 over 20 UF undergraduates have conducted research in my laboratory
Curriculum/Course Development
2010-12
2002-07
2003-2006
Co-Director (with D. Borchelt) Molecular Neurobiology of Disease, Department
of Neuroscience, UF COM.
Mayo Clinic, Together with Dr’s Streheler, Bieber, and Nicolle, I revised the
Molecular Neuroscience Tutorial Courses, Seminar Series (NSCI 8500) and
Journal Clubs (NSCI 8600). This became the first three site model for Graduate
Education at Mayo.
Co-Directed and Developed Animal Models of Disease Course Molecular
Neuroscience. Mayo Clinic Department of Neuroscience
Miscellaneous Teaching Activities
1999-2001
Founder and Coordinator Mayo/Joe Berg Society High School Volunteer
Program. Mayo Clinic Florida
47